University of South Carolina

Scholar Commons
Theses and Dissertations
1-1-2013

The Effect of Thymidylate Synthase Inhibitors On Bone Marrow
Derived Cells In the Intestinal Tumor Microenvironment
Grishma Acharya
University of South Carolina

Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Biology Commons

Recommended Citation
Acharya, G.(2013). The Effect of Thymidylate Synthase Inhibitors On Bone Marrow Derived Cells In the
Intestinal Tumor Microenvironment. (Doctoral dissertation). Retrieved from
https://scholarcommons.sc.edu/etd/2560

This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please
contact digres@mailbox.sc.edu.

THE EFFECT OF THYMIDYLATE SYNTHASE INHIBITORS ON BONE MARROW
DERIVED CELLS IN THE INTESTINAL TUMOR MICROENVIRONMENT
by
GRISHMA ACHARYA
BACHELOR OF TECHNOLOGY
INSTITUTE OF CHARTERED FINANCIAL ANALYSTS OF INDIA, 2007
Submitted in Partial Fulfillment of the Requirements
For the Degree of Doctor of Philosophy in
Biological Sciences
College of Arts and Sciences
University of South Carolina
2013
Accepted by:
Franklin G. Berger, Major Professor
Maria Marjorette O. Pena, Major Professor
Hexin Chen, Committee Chair
Minsub Shim, Committee Member
Robert Price, Committee Member
Lacy Ford, Vice Provost and Dean of Graduate Studies

© Copyright by Grishma Acharya, 2013
All Rights Reserved.

ii

DEDICATION
I dedicate my thesis to my late father Mr. Debendra Nath Acharya who showed
unwavering trust and faith in my abilities throughout his life. I wish to make him proud
through my endeavors to contribute to the world of science.

iii

ACKNOWLEDGEMENTS
This has been quite a journey. The work that I present through my thesis is only a part of
this experience, as it does not include the trials, tribulations, standardizations, and
occasional frustrations omnipresent during the PhD process. I would thus like to
acknowledge all those who have encouraged, supported, assisted me, and made invisible
yet significant contributions to this thesis. To begin, I would like to thank my father,
mother, Uncle Suresh, Aunt Alpana, my mother in law, my father-in-law, my grandfather
Aja, my Aai, and the rest of my family who have always encouraged me to pursue my
dreams and always made enormous efforts towards understanding my passion towards
research. I would like to thank Anmiv S Prabhu for being a pillar of endless emotional
and professional support during these years of graduate studies.
I am very grateful to my advisor Dr. Maria Marjorette Peña, under whose able
guidance I have learned a lot, both professionally and personally. I would like to thank
my amazing lab mates, who are more like friends than colleagues and have made the long
hours in the lab more enjoyable – Nikeya, Tia, Yu, Daniel, Sapana, and John. I would
like to acknowledge my committee members Dr. Frank Berger, Dr. Dan Dixon, Dr.
Robert Price, Dr. Hexin Chen, and Dr. Minsub Shim for being a very approachable and
encouraging committee. I extend my thanks to Dr. Berger‟s lab members Karen, Ufuk,
Sarah, Yang Yang, and Sandra who have been a part of my lab family.
I‟d like to take the opportunity to acknowledge my supportive friends who have
iv

been like an extended family to me - Mouna, Aditi, Swati, Rupa, Anindita, Ronak, and
Atishi. They have shared the joys and trials of research with me, patiently and
uncomplainingly, never once failing to be there for me.

v

ABSTRACT
Tumors have come to be known as independently functioning complex organs consisting
of cancer cells coexisting with a heterogeneous mixture of host-derived non-neoplastic
cells that form the tumor stroma. Tumor survival, progression, and metastasis depend on
multiple close interactions between the cancer cells and the tumor stromal cells. These
tumor stromal cells are mainly bone marrow derived cells (BMDCs) that are recruited to
the primary tumor and sites of metastasis by a variety of signals secreted by the cancer
cells. Because of the close interaction between the tumor and the tumor stroma, we
propose that tumor stromal cells play an important role in tumor response to systemic
treatment with chemotherapeutic agents and that tumor response to therapy will reflect
that of the tumor stroma. By also targeting the tumor stroma with chemotherapy, we can
potentially enhance drug efficacy and specificity. In this study, we used ApcMin/+ mice
that are predisposed to the development of spontaneous adenomatous tumors in the small
intestine and colon, and a Balb/cByJ ectopic mouse model that were subcutaneously
implanted with CT26 colon carcinoma cells. Using these murine models, we identified
and quantitated the myeloid derived suppressor cells (MDSCs), mast cells, and Tregulatory cells (T-regs) in the intestinal tumor stromal compartment. We then
determined if these BMDCs were direct cellular targets of thymidylate synthase (TS)
inhibitors in the tumor stroma by studying the kinetics of their response to the drug 5fluorouracil (5-FU). We validated the impact of TS inhibitors on these target cells in
chimeric ApcMin/+ mice that were generated by transplanting genetically modified bone
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marrow cells, such that the sensitivity of tumor stromal cells to systemic drug treatment
was distinct from that of the tumor cells. The results showed that MDSCs are selectively
sensitive and are direct targets of 5-FU, mast cells are resistant and are recruited the
tumor bed in response to 5-FU, while T-regs are not prominently affected by 5-FU. We
examined the mechanisms underlying the differential effects of 5-FU on MDSCs, mast
cells, and T-regs. The results will lay the foundation for our ultimate goal of developing a
strategy to target TS specifically in the tumor and tumor associated stromal cells using a
single agent while protecting normal, healthy actively dividing cells from the detrimental
effects of these inhibitors.
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CHAPTER 1
INTRODUCTION: A PARADIGM SHIFT
1.1 Hallmarks of cancer, traditionally
The hallmarks of cancer postulated a list of underlying principal properties that
collectively characterize a variety of cancers based on their typical phenotypic behavior
during cancer progression (Hanahan and Weinberg 2000; Hanahan and Weinberg 2011).
These underlying principal traits govern the transformation of normal cells into cancerous
cells. These hallmark properties include the following: (1) cancer cells can stimulate their
own growth, (2) they resist inhibitory signals that might otherwise stop their growth, (3)
they resist programmed cell death (apoptosis), (4) they stimulate the growth of blood
vessels to supply nutrients to tumors (angiogenesis), (5) they can multiply indefinitely,
and (6) for some cells, they can invade local tissue and spread to distant sites
(metastasis). For a long time, it was believed that understanding the biology of just the
cancer cells themselves could explain the complete functioning of a tumor (Kerkar and
Restifo 2012). Because of this, most anti-cancer pharmaco-therapeutic strategies were
traditionally designed to specifically target the cancer cells themselves. Various anticancer therapies include surgical removal of the neoplastic region and are often
accompanied by chemotherapy or radiation therapy targeted directly at the cancer, either
alone or in combination. Even with the variety of available options, traditional anticancer treatment is usually accompanied by detrimental side-effects, such as drug1

induced toxicity to normal cells resulting in hematopoietic and gastrointestinal damage,
and gradual resistance to the chemotherapy (Love, Leventhal et al. 1989; Attar, Ervin et
al. 2000; Burstein 2000; Partridge, Burstein et al. 2001; McKnight 2003). Most therapies
are moderately effective for a short time but are typically followed by accelerated
repopulation of the tumor and a relapse of the disease in most patients. Such challenges
and the failure to conquer the disease have instigated intense research on tumors and their
microenvironment, and new effective therapies are needed while minimizing the toxic
side effects (Ohtsu 2003; Omura 2008; Fujii, Kochi et al. 2010).

1.2 Tumor and the friendly neighborhood microenvironment
In recent years, further research has revealed that cancer cells do not exist as isolated
entities but are in continuous communication with the normal non-neoplastic cells that
are recruited and infiltrate into their surrounding environment. These non-neoplastic
“normal” cells, along with the extracellular matrix in which the tumor is embedded, the
blood vessels, connective tissue, and secreted molecules collectively make up the tumor
microenvironment or the tumor stroma and provide a platform where the tumor can
interact closely with the surrounding stromal cells. This concept was derived from
previous studies by Harold Dvorak in his hypothesis that „tumors are wounds that do not
heal‟ (Dvorak 1986). Under normal homeostatic conditions, a mutated or aberrantly
functional cell is usually eliminated by the body‟s defense mechanism of inflammatory
cells to restore normal homeostasis such as that in the process of wound healing.
However cancer can be considered as a state of continuous disruption of normal
homeostasis, a state that can be viewed as a wound that does not heal, despite the best
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efforts of normal functional cells to try to eliminate it. In this disease state, the normal
cells surrounding the neoplastic cells are confounded by the cancer cells into ignoring the
wound healing process thereby aiding in the survival and replication of the
malfunctioning cancer cells (Dvorak 1986).
Because of the complexity of its structure and composition, tumors have begun to
be viewed as independently functional organs that are comprised of aggressively
proliferating cancer cells coexisting with a heterogeneous mixture of non-neoplastic cells
that provide nourishment and support and create a conducive environment for cancer cell
survival and proliferation (Hanahan and Weinberg 2011; Swartz, Iida et al. 2012). The
composition and proportion of the stroma varies depending on the type and location of
the cancer and depends on the tumor malignancy (Mueller and Fusenig 2004; Sebens and
Schafer 2012).
A major contributor to the tumor microenvironment has been found to be
inflammation and inflammatory mediators. In most cases, tumors generally circumvent
the immune system and evade their intervention by exploiting the inflammatory cells for
pro-survival strategies. These inflammatory cells are predominantly derived from the
hematopoietic system and are thus very varied in their character as well as functions
within the tumor stroma. For example, connective tissue mast cells have been implicated
in tumor progression because they concentrate around tumors prior to the formation of
new blood vessels (Reed, McNutt et al. 1996). Mast cells are also known to be
instrumental in polyp formation resulting in colorectal carcinogenesis (Gounaris, Erdman
et al. 2007). Recruitment of macrophages and mast cells has been observed in the
development of the cervical intraepithelial neoplasia (Utrera-Barillas, Castro-Manrreza et
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al. 2010). T-regulatory cells (T-regs) have been found to suppress protective anti-tumor
immune responses (Gounaris, Blatner et al. 2009). Tumor associated myeloid derived
suppressor cells (MDSCs) have been found to suppress both antigen-specific and
nonspecific T cell activity (Corzo, Condamine et al. 2010) and have been found to
infiltrate tumors that are ectopically implanted in C57BL/6J mice such as MC38 colon
cancers, 3LL (lung carcinomas), B16 melanoma or CT26 tumors in Balb/c mice
(Ostrand-Rosenberg and Sinha 2009). These studies show that inflammatory cells are
highly abundant and in close contact with the cancer cells in the tumor
microenvironment.
The hematopoietic system is a rich source of immature cells from which
inflammatory cells are derived from. Due to its close proximity, molecular signals
secreted by tumor cells can lead to the recruitment of a variety of host-derived cells that
originate from the bone marrow. For example, Udagawa et al. demonstrated that CD31+
cells are recruited from the nearby GFP+ tissue in murine syngeneic lung carcinoma or a
xenogeneic osteosarcoma model to create blood vessels within the tumor (Udagawa,
Puder et al. 2006). Marini et al. and Pittet et al. have shown that tumor associated
fibroblasts, macrophages and neutrophils are derived from the bone marrow (CortezRetamozo, Etzrodt et al. 2012). Recruited bone marrow derived cells (BMDCs) enhanced
tumor progression through paracrine Wnt signaling in the prostrate epithelia of an
orthotopic C4-2B xenograft model (Placencio, Li et al. 2010; Kidd, Spaeth et al. 2012).
Various studies, thus, support the theory that BMDCs actively participate in colonizing
the tumor stroma, and that they are recruited by the cancer cells through a variety of
signaling chemokines (Chantrain, Feron et al. 2008). Tumor infiltrating, bone marrow
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derived inflammatory cells and inflammatory signals have been shown contribute to
cancer growth and spread, and to the immunosuppression associated with malignant
disease, promoting inflammation and vascularization within the tumor (Balkwill and
Mantovani 2001). Because of these, it is important to characterize and understand the
tumor microenvironment particularly with respect to their role in determining the clinical
efficacy of anti-tumor therapy.

1.3 Tumor microenvironment and response to anti-cancer therapy
The close proximity and the complex cross-talk that exists between stromal cells and
cancer cells within the tumor suggest that stromal cells may play a highly influential role
in dictating the tumor‟s response to therapy. Recent studies have shown that the intricate
involvement of tumor stromal cells can define the manner in which cancer cells respond
to different anti-cancer therapies. For example, it has been shown in a rat colon cancer
model that administration of cyclophosphamide delayed the outgrowth of tumors by
depleting T-regs (Ghiringhelli, Larmonier et al. 2004). Tumor response to radiation
therapy was found to be dependent on the apoptotic capacity of infiltrating,
hematopoietic derived endothelial cells (Garcia-Barros et al). Addition of proinflammatory cytokines to bolster cytotoxic T cell response has been found to enhance
the efficacy of radiation therapy (Shiao and Coussens 2010). Tumor infiltration by
lymphocytes has been shown to predict the efficacy of neo-adjuvant chemotherapy
(Denkert, Loibl et al. 2010). Therapeutic interventions with the generation of tumorassociated-macrophages are known to enhance existing anti-cancer therapies in several
different trials (Gerard and Rollins 2001; Duluc, Delneste et al. 2007; Porta, Subhra
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Kumar et al. 2007). Thus, it is critical to identify the key players in the tumor
microenvironment, to elucidate their specific role in cancer progression, and to target
them, along with the cancer cells, to potentially enhance the efficacy of anti-cancer
therapies.
Since the majority of tumor stromal cells are derived from the hematopoietic
system, BMDCs are excellent candidates as targets or as carriers for the systemic delivery
of therapeutic agents and factors that might enhance the efficacy of anti-cancer therapies
(Doering, Archer et al. 2010). Exploiting BMDCs for anti-cancer therapy, therefore, is
the subject of active research in the development of new anti-cancer therapies. The close
synergistic interaction between the cancer cells and the tumor-stromal cells can be
exploited for the effective therapeutic targeting of tumor. BMDCs can be strategically
utilized for systemic delivery of anti-cancer therapeutics (Doering, Archer et al. 2010).
Since an aggressive tumor participates in active recruitment of BMDCs, these BMDCs
can be modified to function as a delivery system. The main advantage of exploiting
BMDCs for enhancing therapeutic efficacy is that they can be conveniently genetically
manipulated ex vivo and then transplanted back into pre-clinical models to systemically
deliver genes that might enhance therapeutic efficacy. For example, bone marrow-derived
mesenchymal stem cells have been used as vehicles to deliver IFN-β to inhibit the growth
of malignant cells in a melanoma model (Studeny, Marini et al. 2002). The pancreatic
tumor stroma has been targeted by transplantation of genetically manipulated
mesenchymal stem cells carrying thymidine kinase resulting in the reduction of tumor
size in an orthotopic model of pancreatic carcinoma (Zischek, Niess et al. 2009).
Engineered BMDCs have been used to selectively eliminate Tie-2 expressing
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mononuclear cells to inhibit angiogenesis in mouse models of mammary carcinoma and
lewis lung carcinoma (De Palma, Venneri et al. 2003). Garcia-Barros et al showed that
apoptosis of cancer cells in response to radiation therapy is dependent on the apoptotic
capacity of the infiltrating hematopoietic cells (Garcia-Barros, Paris et al. 2003). Other
studies have shown that specific targeting of tumor stroma aids in tumor regression and
treatment. Willhauck et al, showed that tumor vascularization and invasion can be greatly
diminished by altering the tumor stroma in squamous cell carcinoma using biodegradable
scaffolds (Willhauck, Mirancea et al. 2007). Mesenchymal stem cells derived from the
bone marrow can be genetically modified to overexpress thymidine kinase and then
utilized in combination with ganciclovir to enhance the reduction of pancreatic tumor
growth and the incidence of metastases significantly (Zischek, Niess et al. 2009). These
studies showed that BMDCs in the microenvironment can have a significant impact on
tumor response to therapy.

1.4 Colorectal cancer: Facts, therapies, and challenges
The role of inflammatory cells in gastrointestinal carcinogenesis has long been
established epidemiologically (Taketo 2009); (Balkwill and Mantovani 2001). It is
estimated that 60-90% of the mass of gastrointestinal tumors is occupied by stroma.
Colorectal cancer is a malignant tumor arising from the inner wall of the large intestine. It
is the third most frequent cancer in males and fourth in females in the United States.
Colorectal cancer is the second leading cause of cancer related mortality (Whitlock, Lin
et al. 2008; Peddareddigari, Wang et al. 2010). Figure 1.1 shows the different stages of
colorectal cancer progression from the development of adenomatous polyps to
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carcinomas and eventually, the initiation of metastasis. In our studies, we will utilize
murine models of colorectal cancer that pertain to different stages of cancer progression.
In human patients, the majority of colorectal cancers are adenocarcinomas, which are
tumors arising from colonic mucosal cells. While most adenocarcinomas are well or
moderately differentiated, approximately 15% are poorly or undifferentiated tumors.
These tumors are typically associated with a poorer prognosis.

Figure 1.1. Colorectal cancer progression. Depicts the
progression of colorectal cancer, from the polyp stage to the
malignant cancer stage (Adapted from Johns Hopkins Medicine,
Sidney Kimmel Comprehensive Cancer Center).

1.5 Thymidylate Synthase
There are several available therapies for the clinical management of colorectal cancer,
including surgical removal of the tumor, chemotherapy commonly involving drug
combinations like FOLFOX (leucovorin, 5-FU, and oxaliplatin) or FOLFIRI (leucovorin,
5-FU, and irinotecan), cryosurgery, radiation therapy and targeted therapy (Dwight,
Higgins et al. 1972; Fong, Kemeny et al. 1996; de Gramont, Figer et al. 2000;
Bokemeyer, Bondarenko et al. 2009). Among the most commonly used chemotherapeutic
agents are the inhibitors of the S-phase enzyme thymidylate synthase (TS). TS catalyzes
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the reductive methylation of 2‟-deoxyuridine-5‟monophophate (dUMP) to 2‟deoxythymidine-5‟monophosphate (dTMP) using 5,10-methylenetetrahydrofolate as a
methyl source, (Figure 1.2) (Rose, Farrell et al. 2002; Costi, Ferrari et al. 2005).
Subsequently, dTMP is phosphorylated to 2‟deoxythymidine-5‟-triphosphate (dTTP)
which is used for DNA synthesis in actively dividing cells (Rose, Farrell et al. 2002;
Costi, Ferrari et al. 2005). This reaction is the sole de novo source of dTTP within the
cell, making TS an important target of anti-cancer agents. Inhibition of the TS enzyme
leads to depletion of thymidine pools, elevation of dUTP pools resulting in misincorporation of uracil into DNA causing DNA damage and ultimately, cellular apoptosis
(Danenberg, Malli et al. 1999; Gmeiner 2005).

Figure 1.2. Thymidylate synthase. Pathway depicting
reductive methylation of dUMP to dTMP by thymidylate
synthase (Adapted from (Rose, Farrell et al. 2002; Costi,
Ferrari et al. 2005).

9

Studies have shown that tumors in general express 2 to 10-fold higher levels of TS as
compared to normal tissues (Parise, Janot et al. 1994; Findlay, Cunningham et al. 1997;
Farrugia, Ford et al. 2003; Mauritz, Giovannetti et al. 2009). Among the earliest classes
of drugs used clinically for TS inhibition are the fluoropyrimidines. A good example is 5fluorouracil (5-FU) which has been used for many decades in the clinical management of
colon and other cancers. In 1957, Heidelberger and his colleagues observed that rat
hepatoma tumors had a higher rate of uracil incorporation into DNA as compared to the
corresponding normal tissue. This research lead to the development of 5-FU, one of the
first class of chemically modified molecules developed as a TS inhibitor anti-neoplastic
drug that are analogs of the TS substrate dUMP (Heidelberger, Chaudhuri et al. 1957). A
fluorine atom was substituted for hydrogen atom at the carbon-5 position of the
pyrimidine ring to create 5-FU which is a competitive inhibitor of TS (Chu, Callender et
al. 2003; Showalter, Showalter et al. 2008). Upon administration, inactive 5-FU is
transported into the cell by facilitated transport using the uracil transporter protein and
then

converted

into

the

powerful

TS

inhibitor

5-fluoro-2‟-deoxyuridine-5‟-

monophosphate (FdUMP) that is covalently bound to TS. In addition to TS inhibition, 5FU can also be incorporated into both cytoplasmic and nuclear RNA molecules (Rose,
Farrell et al. 2002). It can also be mis-incorporated into DNA during DNA biosynthesis
in cancer cells resulting in DNA strand breaks leading to apoptosis. Thus, while induction
of cell death generally involves DNA directed events, 5-FU mediated induction of
apoptosis could also be a consequence of mis-incorporation into RNA.
Although widely used in the clinical management of many cancers, the use of TS
inhibitors is accompanied by severe side effects due its lack of specificity for cancer
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cells. TS inhibitors primarily target rapidly proliferating cells and do not discriminate
between actively dividing cancer cells or normal cells (Grem 2000; Rose, Farrell et al.
2002). Thus actively dividing normal cells such as those in the intestinal tract, the
hematopoietic system, optical system, or hair follicles are equally targeted resulting in
gastrointestinal epithelial ulceration, myelosuppression, ocular toxicity, and harmful
effects on hair follicles or hair loss (Grem 2000; Chu, Callender et al. 2003). Prolonged
administration of TS inhibitors to cancer patients can also gradually induce apoptotic
resistance in cancer cells (Grem 2000).
In order to increase the clinical utility of TS inhibitors, it is necessary to develop
strategies and combination therapies to enhance its cytotoxicity to cancer cells while
minimizing its toxic effects on normal cells. While the impact of TS inhibitors on cancer
cells has been assessed based on tumor burden, their impact on tumor associated stromal
cells is less known. In this study, we examined the effect of TS inhibitors on tumor
associated stromal cells in order to develop novel strategies to enhance their anti-tumor
efficacy and the specificity for cancer cells of these inhibitors.

1.6 Animal model for colorectal cancer studies: the ApcMin/+ mouse
A number of animal models have been used to study colon carcinogenesis, the
mechanisms of its pathogenesis and have been used to establish therapeutic and
preventive treatments (Taketo and Edelmann 2009). One of the most widely used genetic
mouse model for studying the initiation and progression of intestinal tumors is the
ApcMin/+ mouse. This mouse has a germ-line mutation in the adenomatous polyposis coli
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(APC) gene that is similar to that found in approximately 80% of sporadic colon cancer
in humans (Dove, Gould et al. 1995). Tumor development mimics that in patients with
Familial Adenomatous Polyposis (FAP), an inherited form of colon cancer which is also
caused by a mutation in the APC gene (Shoemaker, Gould et al. 1997). The multiple
intestinal neoplasia (Min) is a mutant allele of the murine APC locus, encoding a
nonsense mutation at codon 850. It has a transversion point mutation that alters
nucleotide 2549 from a T to an A that converts codon 850 from one encoding a leucine to
a stop codon resulting in a truncated polypeptide. These mice are predisposed to the
spontaneous development of multiple adenomas predominantly in the small intestine with
a few in the colon (Shoemaker, Gould et al. 1997). The animals typically die within four
to six months due to severe anemia and intestinal blockage by tumors. These mice
provide a convenient model to test the effect of a drug therapy and their modulations
because their impact can be readily measured by counting intestinal tumors and
measuring their size in the mouse pre- and post- treatment. Also, it is known that the
intestinal stroma of ApcMin/+ mice is highly infiltrated by hematopoietic derived cells
(Erdman and Poutahidis 2010; Davis, Price et al. 2011). Nevertheless, the exact cellular
constitution of the ApcMin/+ mouse intestinal tumor stroma as well as the functional role of
each cell type in modulating the response of cancer cells towards therapy using TS
inhibitors, has not been elucidated. Thus the ApcMin/+ mouse has facilitated our study of
stromal cell populations and their response to TS inhibitors.
1.7 Animal model for colorectal cancer studies: CT26-derived subcutaneous tumor
implantation model in Balb/cByJ mice
Balb/cByJ mice have been used as immune-competent hosts for the subcutaneous
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implantation of syngeneic immortalized cell lines. In this study we used eight-week old
Balb/cByJ mice for subcutaneous implantation of the mouse CT26 colon carcinoma cell
line as a model to study more advanced stage of cancer as compared to adenomas in
ApcMin/+ mice. CT26 is an undifferentiated murine colon carcinoma cell line derived from
Balb/cByJ mice after treatment with N-nitroso-N-methylurethane, a chemical mutagen.
CT26 cells proliferate like malignant tumors when injected subcutaneously or
orthotopically into the cecum of Balb/cByJ mice. These cells have been used to test
immunotherapy protocols and in several studies examining host immune responses.
Two weeks post injection of 1 million CT26 cells into the flank; the Balb/cByJ
mice develop tumors with 9-11 mm diameter, that can be excised, de-bulked, and the
resulting single cell suspension used for various analyses. This model provides a good
platform for cancers that mimic the aggressiveness and disease morphology of human
colorectal carcinoma. Furthermore, these cells can give rise to liver metastases when
injected into the cecum providing an opportunity to study colon cancer progression at
various stages of the disease. For the purpose of this research, both of these animal
models have provided a convenient means to test our hypothesis.

1.8 Overall goal of this project
The overall goal of this study was to test the hypothesis that tumor response to systemic
treatment using TS inhibitors is determined by the chemo-sensitivity of tumor infiltrating
hematopoietic-derived stromal cells. Previous data had shown that, when transplanted
with bone marrow overexpressing e.coli.TS, ApcMin/+ mice were capable of refracting a
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combination therapy of 5-FU and Raltitrexed drugs, suggesting the possible presence of
BMDCs in the intestinal tumor stroma influencing tumor response to chemotherapy. Thus
specifically, our objectives were: 1) to identify the bone marrow derived cellular
components of the intestinal tumor microenvironment; 2) to identify the cells that might
be the direct targets of TS inhibitors; and 3) to analyze the effect of TS inhibitors on
various hematopoietic derived tumor stromal cells. Our ultimate goal is to enhance the
efficacy and tumor specificity of TS inhibitors by simultaneously targeting the tumor and
tumor-associated stromal cells with chemotherapy using TS inhibitors without affecting
the normal healthy non-cancerous cells.
1.9 Innovation of the research
Research regarding cancer cell dependency on tumor stroma would alter the general
perspective for the chemotherapeutic targeting of tumor cells. A paradigm shift towards
targeting specific pro-tumorigenic non-neoplastic cells in the tumor periphery along with
directly attacking the cancer cells would ensure a better killing of cancer cells and
prevent relapse, thereby increasing patient survival. In this study, we localized and
quantitated a variety of hematopoietic derived cells in the intestinal tumor
microenvironment including MDSCs, mast cells, and T-regs. We then examined the
effect of 5-FU on these cells and studied the underlying mechanisms of the manner in
which 5-FU affects these cells. Understanding the effect and kinetics of 5-FU on different
BMDCs in the intestinal tumor stroma, can be exploited to develop a strategy to target TS
specifically in both tumor and tumor stromal cells only using a single agent while causing
negligible distress to normal, healthy actively dividing cells.
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1.10 Engraftment of hematopoietic derived cells in the ApcMin/+ recipient mice
In previous studies, the contribution of BMDCs to the intestinal tumor microenvironment
was determined by transplanting bone marrow cells from transgenic mice expressing
eGFP into recipient ApcMin/+ mice (Davis, Price et al. 2011). Donor marrow from
C57BL/6-UB1-GFP mice, expressing eGFP under the control of the human ubiquitin
promoter was isolated from the femur and tibia. The eGFP-expressing bone marrow cells
were then transplanted via tail vein injection into age-matched, lethally-irradiated (950
rads) ApcMin/+ mice (Figure 1.3).

Figure 1.3. Schematic of bone marrow transplantation. eGFP expressing bone
marrow cells were isolated by flushing the femur and tibia of 4-weeks old C57BL/6UB1-GFP transgenic mice and transplanted into a lethally irradiated, age-matched
ApcMin/+ mice by tail vein injection. (Please see text for details)

To determine the distribution of BMDCs in the intestinal tract, intestinal tumor
microenvironment, and in other organs, sections from these various organs were obtained
from the transplanted ApcMin/+ mice and analyzed by confocal microscopy. Eight weeks
after transplantation, intestines, spleen, and liver were excised from the recipient mice,
fixed in 4% paraformaldehyde and then sectioned for analyses by immuno-fluorescence
microscopy. The sections were stained with phalloidin conjugated to Alexa 633 (for
tissue morphology) and imaged using a Zeiss LSM510 META confocal laser scanning
microscope. Figure 1.4 shows that the transplanted eGFP expressing marrow successfully
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engrafted into the gastrointestinal tract of recipient ApcMin/+ mice. eGFP expressing
BMDCs were found abundantly in the small intestine sections, infiltrating both the tumor
and the surrounding normal villi. On the other hand, in the colon sections from the
transplanted mice, BMDCs appear to preferentially infiltrate the tumors, as compared to
the surrounding normal areas (Davis, Price et al. 2011). As a control, sections taken from
untransplanted C57BL/6J wild type mice and untransplanted ApcMin/+ mouse intestines
were also analyzed. Engraftment of eGFP expressing bone marrow derived cells in the
intestine was shown to occur in a gradient fashion, with greater infiltration in the
proximal regions as compared to that in the distal intestinal region and the colon (Davis,
Price et al. 2011). This was observed in both ApcMin/+ and wild type C57BL/6J control
mice and is therefore independent of the ApcMin/+ allele (Davis, Price et al. 2011). These
data showed that indeed, BMDCs are a major component of the cells that make up the
intestinal tumor microenvironment in the ApcMin/+ mouse.
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Figure 1.4. Localization of eGFP expressing BMDCs in the intestinal tumor
stroma. Intestinal sections from ApcMin/+ mice transplanted with eGFP expressing
marrow were stained with phalloidin conjugated to Alexa-633 and analyzed by
confocal microscopy. Donor-derived BMDCs efficiently repopulated and infiltrated
both normal and tumor areas in the small intestine. A. Section from small intestine of
untransplanted C57BL/6J control mouse (10x magnification), B. Small intestine
section containing a tumor from untransplanted ApcMin/+ mouse (10x magnification) C,
D. Intestinal adenoma and surrounding areas of ApcMin/+mice transplanted with eGFP
expressing bone marrow. Red = Phalloidin for actin, Green = GFP.

Examination of other organs showed that there was an extensive engraftment of
eGFP+ BMDCs in the hematopoietic organs like spleen and lung. As compared to that,
there is a significantly low level engraftment of BMDCs expressing eGFP in other organs
like the heart, soleus muscle, kidney and liver in the recipient ApcMin/+ mice (Davis, Price
et al. 2011).
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Spleen (10x image)

Liver (10x image)

Spleen (40x image)

Liver (40x image)

Figure 1.5. Bone marrow engraftment in recipient organs.
Engraftment of donor-derived GFP+ BMDCs in the spleen and liver
of the recipient ApcMin/+ mice. Blue = DAPI, Green = GFP. Spleen
being a hematopoietic organ has a much higher level of eGFP+
BMDCs as compared to their sporadic presence in the liver.

1.11 Preliminary studies
To assess the role of tumor stromal BMDCs in tumor response to therapy, previous
studies were carried out wherein BMDCs in the tumor microenvironment were made
resistant to TS inhibitors while keeping tumor cells sensitive to the therapy (Pena et. al.,
unpublished data). The overall strategy used in the study is outlined in Figure 1.6.
Briefly, bone marrow from transgenic donor mice expressing the enhanced green
fluorescent protein eGFP were genetically modified by transduction with the E. coli TS
gene that conferred enhanced resistance to TS inhibitors as compared to non-transduced
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cells. These were transplanted into lethally irradiated ApcMin/+ mice and resulted in the
creation of chimeric mice wherein the sensitivity of the tumor stromal cells was different
from that of the tumor cells. After full engraftment of the transplanted marrow, the
chimeric mice were subjected to systemic drug therapy using a combination of TS
inhibitors. This therapeutic schedule had previously been shown to decrease tumor
burden in ApcMin/+ mice by 80% (Murphy, Tucker et al. 2004). As controls, ApcMin/+ mice
transplanted with non-transduced, chemosensitive marrow were also subjected to the
same systemic therapy.

MSCV

e.coli. TS

MSCV

+500nM Raltitrexed ,
+ 5uM DIP

+ 150mg/kg
5-FU

Bone marrow
+ IL-6,
+ IL-3, + SCF

GP+E86 retroviral
producer cells

Recipient’s
response to TS
inhibitor therapy

Lethally irradiated
ApcMin/+

Bone marrow
resistance to TS
inhibitors ex vivo

Figure 1.6. Schematic of overall strategy. This schematic outlines the method for
isolating bone marrow from a donor C57BL/6J mouse, then co-culturing them with
retroviral producer cells carrying the expression of e.coli. TS and subsequently
transplanting the genetically modified BMDCs into lethally irradiated ApcMin/+ mice.
Using this protocol in the previous studies, chimeric mice were genetically engineered
to have tumors whose response to chemotherapy is different from that of the tumor
infiltrating BMDCs and the effect of TS inhibitors was studied on the tumor response
to chemotherapy in these mice (Please see text for details.)
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The results showed that when subjected to a combination of the TS inhibitors
Raltitrexed and 5-FU, tumors in the chimeric mice were refractile to the therapy. On the
other hand, age-matched control ApcMin/+ mice transplanted with non-transduced marrow
showed an 80% reduction in tumor burden similar to that in untransplanted ApcMin/+ mice
when subjected to the same chemotherapy regime. The results from these studies
provided the basis for further investigations carried out in the following sections.

1.12 Cellular constituents of the inflammatory microenvironment of intestinal tumor
stroma
There are numerous types of BMDCs that can potentially be found in the intestinal tumor
microenvironment. These cells are listed in Table 1.1 together with the specific cell
surface markers that can be used to identify them. In this study, we focused our efforts to
understand the impact of TS inhibitors on three major cell types that have been shown in
previous studies to play important roles in polyp development and tumor progression in
ApcMin/+ mice and also have been shown to interact with each another for survival within
the tumor microenvironment and for promoting tumor development. These host-derived
BMDCs include the myeloid derived suppressor cells (MDSCs), mast cells, and T-regs.
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Table 1.1. Potential cellular constituents of tumor stroma.

This is a list of a variety of immune cells that are potential components of the
tumor microenvironment. The table outlines different immune-derived cells in the
tumor microenvironment, as well as the respective cell-specific biomarkers used
for their identification.

Myeloid Derived Suppressor Cells: The term myeloid derived suppressor cells, is
used to define a heterogeneous population of immature myeloid cells derived from bone
marrow hematopoietic precursors in mice. They remain undifferentiated under chronic
inflammatory condition altering myelopoiesis that is typical of the tumor stroma
(Baniyash 2006; Ostrand-Rosenberg and Sinha 2009; Umansky and Sevko 2012; Wu,
Yan et al. 2012). MDSCs have been found to accumulate in human patients as well as in
mice with cancer. MDSCs in tumor-bearing mice express the cell surface markers CD11b
and Gr-1 antigens and have the potential to suppress immune responses of T-lymphocytes
in vitro and in vivo (Gabrilovich, Bronte et al. 2007; Marigo, Dolcetti et al. 2008;
Murdoch, Muthana et al. 2008; Gabrilovich and Nagaraj 2009; Peranzoni, Zilio et al.
2010). They are recruited by the tumor cells and host tumor stromal cells into the tumor
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stroma and they have also been shown to accumulate after bacterial attack, parasitic
infection, chemotherapy, and stress. Their accumulation leads to immune dysfunction in
cancer patients due to their immunosuppressive functions (Jutila, Kroese et al. 1988;
Nagendra and Schlueter 2004; Sunderkotter, Nikolic et al. 2004; Dolcetti, Marigo et al.
2008; Huang, Lei et al. 2008; Movahedi, Guilliams et al. 2008; Youn, Nagaraj et al.
2008; Abbitt, Cotter et al. 2009; Ostrand-Rosenberg and Sinha 2009; Ribechini, Leenen
et al. 2009; Dolcetti, Peranzoni et al. 2010). In the tumor microenvironment, they are
known to secrete various immunosuppressive molecules in variable quantities (depending
on their location) such as arginase, inducible nitric oxide synthase, and reactive oxygen
species. They also assist tumors in developing resistance to chemotherapy by secreting
nitric oxide allowing them to avoid the caspase mediated apoptotic cascade (Bronte,
Serafini et al. 2003; Bronte, Serafini et al. 2003; Kusmartsev and Gabrilovich 2003;
Kusmartsev, Nefedova et al. 2004; Sinha, Clements et al. 2007; Sebens and Schafer
2012; Umansky and Sevko 2012). Their accumulation has been documented in the bone
marrow, spleen, and peripheral blood of most patients and mice with cancer, where they
are induced by various factors produced by tumor cells and/or by host cells in the tumor
microenvironment (Almand, Clark et al. 2001; Pflugh, Maher et al. 2002; Gabrilovich
2004; Serafini, Carbley et al. 2004; Kusmartsev, Nagaraj et al. 2005; Sica and Bronte
2007; Dolcetti, Marigo et al. 2008; Haile, von Wasielewski et al. 2008; Marigo, Dolcetti
et al. 2008; Markiewski, DeAngelis et al. 2008; Sinha, Okoro et al. 2008; Umemura, Saio
et al. 2008; Youn, Nagaraj et al. 2008; Abbitt, Cotter et al. 2009; Diaz-Montero, Salem et
al. 2009; Greifenberg, Ribechini et al. 2009).
MDSCs are mainly influenced by either tumor derived factors or by factors
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released by activated T cells and other tumor stromal cells. Tumor derived factors help to
stimulate myelopoiesis and assist myeloid cells in remaining undifferentiated. On the
other hand, activated T cells and tumor stromal cells act by directly activating MDSCs
through stimulating factors like Interferon-γ (IFN-ɤ), Toll like receptors, Interleukins 3
and 4, and Transforming growth factor β (TGF-β). These activated MDSCs in return
release iNOS, arginase I, TGFβ, Cyclin D1, Myc and Survivin (Marigo, Dolcetti et al.
2008; Gabrilovich and Nagaraj 2009; Condamine and Gabrilovich 2011; Sonda, Chioda
et al. 2011). They express low levels of the major histocompatibility complex (MHC)
class II and CD80, a co-stimulatory signal necessary for T-cell activation and survival.
MDSCs also have the ability to induce T-regs expansion and function synergistically with
them to promote the suppression of T-cell activation and down regulate cell-mediated
immunity (Peranzoni, Zilio et al. 2010).
T-regulatory cells: T-regs have been identified as the primary mediators of
peripheral tolerance (Ling, Pratap et al. 2007). Stromal infiltration of T-regs has been
found to be elevated in colorectal cancer patients. They are known to suppress tumorspecific immunity by suppressing CD4+ T cells in part by competing for IL-2, rendering
CD8+ T cells inactive via cell contact and by TGF-β (Gounaris, Erdman et al. 2007;
Mougiakakos, Choudhury et al. 2010). Adoptive transfer of anti-inflammatory T-regs has
previously been shown to suppress polyposis in ApcMin/+ mice in an IL-10 dependent
manner (Gounaris, Blatner et al. 2009). However, under the influence of strong
inflammatory stimuli within the polyp microenvironment, they can convert into proinflammatory IL-17 producing cells (Th17) that help promote colorectal cancer
progression (Colombo and Piconese 2007). Many murine tumor model studies have
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shown that targeting T-regs by depletion might help enhance anti-tumor response (Yang,
Zhang et al. 2010). Studies on the role of T-regs in inflammation associated cancer have
presented a lot of conflicting and paradoxical data. T-regs are a well-known subtype of
immunosuppressive cells that are recruited to the tumor sites by colon cancer cells
producing the chemokine CCL5, to suppress anti-tumor cytotoxic responses (Woo, Chu
et al. 2001; Wolf, Wolf et al. 2003; Okita, Saeki et al. 2005; Bettelli, Carrier et al. 2006;
Ling, Pratap et al. 2007; Siddiqui, Frigola et al. 2007; Clark, Huang et al. 2008;
Giannopoulos, Schmitt et al. 2008; Soria and Ben-Baruch 2008; Sugasawa, Ichikura et al.
2008; Cambien, Karimdjee et al. 2009; Erdman and Poutahidis 2010; Lin, Mahalingam et
al. 2013); and to control self-antigen specific responses in the periphery (Clarke, Betts et
al. 2006). Also, their numbers have been found to be highly inflated in draining lymph
nodes and in peripheral blood in most human cancers (Loddenkemper, Schernus et al.
2006; Ling, Pratap et al. 2007). Expression of the integrin CD103 surface molecule in
effector CD4+Foxp3hiCD45RA- T-regs guides them to an inflamed site of activation and
they accumulate in chronic inflammation, graft-vs-host disease, as well as cancer to
enable the loss of immune-surveillance and enhance tumor-immunosuppression
(Kettunen, Kettunen et al. 2003; Hall, Fortney et al. 2004; Jin, Shido et al. 2006;
Hofmeister, Schrama et al. 2008; Hanna, Quick et al. 2009; Jenq and van den Brink
2010). In humans, T-regs are known to secrete various cytokines such as IL-10 and
TGFB, or IL-17 to suppress the expansion of effector T cells or anti-tumoral peripheral
CD8+ T cells for cancer development (Levings, Bacchetta et al. 2002; Ma and Dong
2011). Depletion of T-regs by different mechanisms has been shown to be a successful
anti-cancer therapy by a variety of studies (Schabowsky, Madireddi et al. 2007).
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Cytotoxic drugs like cyclophosphamide, 5-FU, gemcitabine, and/or oxaliplatin have been
used in preclinical models to deplete T-regs and have been found to correlate with a
better response to treatment (Ghiringhelli, Larmonier et al. 2004; Lutsiak, Semnani et al.
2005; Correale, Rotundo et al. 2010).
There is approximately a 20-fold increase in the numbers of T-regs infiltrating
colorectal tumor stroma as compared to the healthy normal colonic mucosa or colonic
lamina propia (Lin, Mahalingam et al. 2013). In colorectal cancer, specifically, the
expression of Foxp3, a member of the fork head and winged helix family of
transcriptional regulators, is essential for the tumor stroma infiltrating CD4+CD25+ Tregs (Ziegler 2006). Foxp3 is also crucial for the ability of T-reg cells to actively suppress
a variety of immune cells such as dendritic cells, natural killer T cells, CD8+ T cells,
CD4+CD25- T and B cells (Beyer and Schultze 2006). Foxp3+ T-regs with a deletion of
IL-10 are in fact known to contribute to colonic disease and IL-10 producing Foxp3+ Tregs are enriched within the colon during murine colitis (Li, Hsieh et al. 2009; Kaler,
Galea et al. 2010). During active inflammation, circulating T-regs migrate into the lamina
propia to maintain homeostasis (Muzes, Molnar et al. 2012). The vastly utilized animal
model to study colorectal cancer, ApcMin/+ mice, in fact have a higher serum levels of IL6, TNF- and IL-17 as compared to their age matched C57BL/6J counterparts (Erdman
and Poutahidis 2010). Thus, studying the interaction of pro-inflammatory T-regs with
other bone marrow derived immune cells, is crucial to understanding the mechanisms
underlying the tumor response to anti-cancer therapies.
In the context of interacting with other cell-types, specifically in colorectal
cancer, T-regs have been found to interact with mast cells very closely in the tumor
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stroma. This interaction, combined with other tumor-generated inflammatory cytokines
induces the T-regs to switch into a pro-tumorigenic suppressive characteristic, in an IL-6
and IL-17 dependent manner (Blatner, Bonertz et al. 2010). T-regs show pro-tumorigenic
activity in the colorectal tumor stroma by maintaining mast cell activation to promote
polyposis by secreting IL-17 and by being IL-10 deficient.
Mast cells: Mast cells have been studied widely in adenomatous polyp initiation
in ApcMin/+ mice and have been found to be required for tumor initiation and development
(Shinar, Milo et al. 2007). They are derived from bone-marrow hematopoietic progenitors
but migrate, while still immature, from vascular to peripheral tissues and participate in
stroma re-modeling (Yang, Zhang et al. 2010; Liu, Zhang et al. 2011). Mast cells are
known to infiltrate the tumor stroma aggressively in the early stages of tumor
development. While still immature, these hematopoietic derived mast cell progenitors
tend to travel from the vascular to peripheral tissues in a sialomucin dependent manner,
into areas where they can mature and reside. Under normal conditions, mast cells are
known to locate themselves in areas where they can ward off external attacks as quickly
as possible, such as blood vessels, nerves, mucosal surface, skin, respiratory tract, and the
gastro-intestinal tract (Bauer and Razin 2000; Heib, Becker et al. 2008; Liu, Zhang et al.
2011). Although their specific role in tumor stroma remodeling and malignant
transformation is yet unclear, they have been suspected to participate in angiogenesis and
tumor initiation in adenomatous polyps, skin dysplasia, malignant melanoma, breast
carcinoma, and colorectal cancer (Maltby, Khazaie et al. 2009; Liu, Zhang et al. 2011).
Tumor cells are speculated to recruit mast cells to the tumor sites by secretion of stem
cell factors that eventually binds to its receptor c-kit on mast cells. There is also a
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possibility that in a dysregulated tumor stroma, mast cells reprogram tumor cells to obtain
c-kit signaling by transferring the receptor through autocrine or paracrine secretion
(Kitamura and Fujita 1989; Huang, Lei et al. 2008; Liu, Zhang et al. 2011). Postrecruitment, mast cells have been shown to survive in the tumor stroma using the
cytokine IL-9 which is secreted by pro-inflammatory FOXP3+IL-10-IL-17+ T-regs, thus
feeding into the interconnected network among the mast cells, T-regs, and MDSCs.
In their activated form, mast cells release several mediators that are pre-formed in
the cells and stored as granules. These preformed mediators range from histamine
granules to de novo synthesized lipid mediators, cytokines, and chemokines, and they are
released when mast cells face direct injury, cross-linking of IgE receptors, or complement
activation (Prussin and Metcalfe 2003; Dawicki and Marshall 2007; Sanchez-Munoz,
Dominguez-Lopez et al. 2008).
MDSCs, mast cells, T-regulatory cells form a closely knit network of cells that
function synergistically and are crucially involved in various aspects of colorectal
carcinogenesis (Figure 1.7).
Although different aspects pertaining to these cell-types have been studied, the
impact of TS inhibitors on these cells, particularly in a model of colorectal cancer has not
yet been studied or elucidated. This study examines the effect of 5-FU, a therapeutic
agent that has been used for decades, on MDSCs, mast cells and T-regs in the intestinal
tumor stroma as well as in the stroma of an ectopic model of murine colorectal
carcinoma. In the subsequent sections, we have localized and quantitated these specific
BMDCs and we have also studied the kinetics of the effect of a single dose of
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systemically administered 5-FU on these cells in the tumor beds and in the hematopoietic
organs. The results suggest that due to their higher rate of proliferation, MDSCs are more
sensitive to 5-FU as compared to the mast cells in the tumor stroma.
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FOXP3+ IL-10+ IL-17-
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Figure 1.7. Interactions between tumor stromal cells. Close interaction network of
myeloid derived suppressor cells, T-regulatory cells, and mast cells in the intestinal
tumor microenvironment. (See text for details).
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CHAPTER 2
QUANTITATION AND LOCALIZATION OF BONE MARROW DERIVED CELLS
INFILTRATING THE TUMOR STROMA

2.1 Introduction
Colorectal cancer is the second leading cause of cancer-related mortality in the United
States. Despite advances in available techniques for treating colorectal cancer at various
stages of the disease, the majority of patients remain incurable and existing therapies are
only of limited effectiveness due to accompanying limitations. Many of the treatment
options used in the clinical management of the disease include a combination of
chemotherapy with targeted therapy; however, not much has been studied with respect to
the effect of these therapies on the tumor stromal cells in colorectal cancer
microenvironment.
Several

studies

have

been

reported

attempting

to

characterize

the

microenvironment of a variety of gastrointestinal tumors. Patient prognosis is reportedly
impacted by the density, type and location of inflammatory activity within the colorectal
tumor microenvironment (Galon, Costes et al. 2006; McLean, Murray et al. 2011).
Preclinical studies have also demonstrated increased effectiveness of chemotherapy by
combining it with the targeting of a variety of tumor stromal cells. For example, follicular
dendritic cells inhibited apoptotic response of transformed B-cells to etoposide,
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cyclophosphamide, busulfan (Schwarz, Yang et al. 1999). Tumor response to radiation
therapy was shown to be dependent on apoptotic capacity of hematopoietic derived
stromal endothelial cells and cytotoxic T cells (Garcia-Barros, Paris et al. 2003;
DeNardo, Brennan et al. 2011). Thus, in order to understand colorectal carcinogenesis
and develop effective therapeutic strategies, it is important to identify the key cellular
players within the intestinal tumor stroma that are involved in initiating and maintaining
the elevated inflammatory level to promote a pro-tumorigenic environment. With better
characterization of infiltrating immune cells, the precise role of inflammation in the
tumor stroma can be understood and exploited to enhance tumor sensitivity to therapy.
Tumor progression and sustenance depend heavily on a receptive microenvironment. In
colorectal cancer, this tumor-supportive microenvironment includes the co-dependent
existence and functioning of the MDSCs, mast cells, and T-regs interacting closely at
various stages from polyposis and progression to adenoma, to carcinoma, and ultimately
metastasis.
Mast cells are thought to play a tumor-protective role in intestinal immunesurveillance. Activated mast cells in the colorectal tumor stroma secrete various proinflammatory mediators, small molecules, and cytokines involved in leukocyte
recruitment and activation, vasodilation, angiogenesis, and mitogenesis (Frankenstein,
Alon et al. 2006; Bischoff and Kramer 2007; Theoharides, Kempuraj et al. 2007;
Sinnamon, Carter et al. 2008). Activated mast cells also have an immense ability to
recruit cells by secreting cytokines such as, CCL2, IL-10 and IL-13, that result in the
recruitment of immune-suppressive CCR2+ cells such as, MDSCs. The MDSCs that are
mobilized into the colorectal tumor stroma function effectively by remodeling the stromal
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architecture making it more immune-suppressive and less anti-tumorigenic, permitting
the further development of aggressive polyps (Yang, Zhang et al. 2010). Once in the
tumor stroma, MDSCs also produce massive amounts of pro-inflammatory IL-17 that inturn contributes to the maintenance of activated mast cells. MDSCs also promote the
migration and development of other immune-suppressive cells such as pro-inflammatory
IL-10-IL-17+FOXP3+ T-regs by secreting cytokines like IL-17 and IFN-γ (Colombo and
Piconese 2009; Gounaris, Blatner et al. 2009).
The anti-inflammatory and tumor reprogrammed IL-10-IL-17+ T-regs play a role
in tumor maintenance and progression by secreting cytokines such as IL-17 mainly to aid
in the recruitment of pro-tumorigenic mast cells (Colombo and Piconese 2009; Gounaris,
Blatner et al. 2009). Although, normal T-regs are known to inhibit histamine release by
mast cells, they act in a pro-tumorigenic polyp initiating manner by promoting the mast
cell mediated release of TNF-α in the tumor stroma (Colombo and Piconese 2009). They
are also thought to recruit and expand mast cell proliferation in an IL-9 dependent
manner (Gounaris, Blatner et al. 2009).
In this study, we localized and quantitated the MDSCs, mast cells, and T-regs in
intestinal tumor microenvironment using two animal models of colorectal cancer. The
ApcMin/+ mouse, a genetic model of colon carcinogenesis, and an ectopic model of colon
carcinoma using Balb/cByJ mice. ApcMin/+ mice are predisposed to the spontaneous
development of multiple adenomas mostly in the small intestine with a few in the colon,
however these tumors never progress to the carcinoma stage or metastasize to distant
organs. In the ectopic model, Balb/cByJ mice are used as immune-competent hosts for
the subcutaneous implantation of syngeneic immortalized murine cancer cell lines. We
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used eight-week old Balb/cByJ mice for subcutaneous implantation of CT26 mouse colon
adenocarcinoma cells as a model to study a more advanced stage of cancer as compared
to the adenomas in ApcMin/+ mice. CT26 proliferate as malignant tumors when injected
subcutaneously or into the cecum of Balb/cByJ mice. Two weeks post-injection, the mice
develop a large tumor that can be excised and the cells utilized for further analyses by
confocal microscopy or flow cytometry. Furthermore, when injected into the cecum, they
spontaneously give rise to liver metastases, providing an opportunity to study colon
cancer progression at various stages of the disease. The ectopic model progresses much
faster than tumor development in the ApcMin/+ mice, thus providing an alternative model
where we can examine the role of BMDCs in tumorigenesis and tumor response to TS
inhibitors within a defined time frame.
To develop therapies targeting the tumor and cells in the tumor stroma, it is
crucial to confirm that the target cells indeed reside within the tumor and are localized to
the microenvironment of intestinal tumors. These localization studies will confirm the
infiltration of bone marrow derived MDSCs (Monocytes and Granulocytes), mast cells,
and T-regs in the adenomas and carcinomas of both mouse models. The distribution of
the cell types within the tumor microenvironment were established by confocal
microscopy, while the abundance of each cell type was determined by flow cytometry.
The results from these studies will provide a baseline measurement for (a)
comparing the tumor dependent immune cell recruitment to tumor stroma, and (b)
measuring the quantitative effect of TS inhibitors on these BMDCs. The abundance of
these host-derived immune-cells were simultaneously quantitated in the tumor beds as
well as hematopoietic organs of tumor-bearing mice and compared to that in normal non32

inflamed hematopoietic organs of age-matched non-tumor bearing C57BL/6J and
Balb/cByJ mice.

2.2 Material and Methods
Cell Culture: CT26 cells are derived from Balb/cByJ mice by mutagenesis using Nnitroso-N-methylurethane-(NNMU). They were purchased from the American Type
Culture Collection (ATCC), and grown in monolayer in Dulbecco's Modified Eagle
Medium (DMEM) supplemented with 10% heat inactivated Fetal Bovine Serum (FBS)
(Atlanta

Biologicals,

Lawrenceville,

GA),

2

mmol/L

L-glutamine,

and

1×

penicillin/streptomycin (Mediatech, Manassas, VA) at 37oC and 5% CO2 in a humidified
atmosphere, until they reached 90% confluence. They were trypsinized with 0.25%
trypsin in 2.21 mM EDTA (Mediatech, Manassas, VA) for 5 minutes. 5 ml of DMEM
supplemented with 10% heat inactivated FBS was then added to the trypsinized cells to
inactivate the trypsin. The cells were then centrifuged at 3000 rpm for 5 minutes. Upon
centrifugation, the supernatant was discarded and the pellet disintegrated with 5 ml of
sterile phosphate buffered saline (PBS) used as wash buffer, to remove traces of FBS
from the cell preparation. The mixture was the centrifuged for 5 minutes at 3000 rpm and
the pellet thus obtained is re-suspended in 1 ml PBS.

The harvested CT26 cells

suspended in sterile PBS are then ready for subcutaneous implantation.
Mice: Balb/cByJ mice, C57BL/6J-ApcMin/J mice (ApcMin/+) and C57BL/6J mice were
purchased from the Jackson Laboratories (Bar Harbor, ME, USA) but were bred and
maintained at the Mouse Experimentation Core Facility of the Center for Colon Cancer
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Research at the University of South Carolina (USC), Columbia, SC. All aspects of the
animal experiments were conducted in accordance with the guidelines and approval of
the USC Institutional Animal Care and Use Committee.
Subcutaneous injection into Balb/c mice: One million CT26 cells were injected with
subcutaneously into the flank of eight-week old Balb/cByJ mice. After 1 week, tumors
were measured daily and excised when they reached a diameter of about 9-11 mm (about
10-14 days post implantation).
Isolation of single cell suspensions from tumors and other organs:
Balb/cByJ mice: Tumor bearing Balb/cByJ mice were humanely sacrificed and tumors
excised. Tumors were sliced into smaller pieces using a sterile scalpel and then
enzymatically digested with collagenase I (5mg/ml), collagenase IV (5mg/ml),
hyaluronidase V (2.5mg/ml) and DNase I (1mg/ml). The tissue/enzyme mixture was
placed in a 37oC shaker for 30 minutes then filtered using 70-micron nylon filter. The
flow-through was centrifuged at 2000 rpm for 5 minutes using an Eppendorf 5430R
microcentrifuge at room temperature and the supernatant discarded. The pellet free of
media and enzyme was then processed as described in the protocol for flow cytometry
analysis in the following section.
ApcMin/+ mice: 15-week old ApcMin/+ mice were humanely sacrificed. Intestines and colon
were isolated, connective tissue removed, and the small intestine divided into four
sections with the colon as the fifth segment. Each section was flushed with PBS to
remove fecal matter and then sliced longitudinally. Intestinal tumors were excised under
a dissecting microscope. Tumors from intestines and colons from each group of mice,
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PBS or 5-FU, were combined together for each time point. They were then mechanically
disintegrated and passed through a 70-micron nylon filter to obtain a single cell
suspension containing a mixture of tumor and stromal cells.
Spleen: Spleens were isolated from the mice. Spleens from the same treatment group,
PBS or 5-FU, were combined and processed together by homogenization. 1ml of PBS
containing 2% FBS solution was then added to the homogenized tissues. The mixture was
then passed through a 70 micron nylon cell strainer to obtain a single cell suspension.
Bone marrow: Bone marrow was flushed from the femur and tibia of the mice using a 21
gauge syringe containing PBS with 2% FBS, and passed through the 70 micron nylon cell
strainer to remove bone debris and other impurities. Bone marrow from 5 mice from each
group, PBS or 5-FU, were combined for further analysis. The resulting single cell
suspension was then prepared for analyses by flow cytometry as described below.
Analysis of cells by flow cytometry: The single cell suspensions obtained from the tumors
and organs were incubated in ammonium chloride lysis buffer (150 mM NH4Cl, 10 mM
Na2CO3, 0.1 mM EDTA, pH 7.4) for 10 minutes on ice, in the dark, to lyse the red blood
cells, followed by centrifugation at 2000 rpm for 5 minutes at room temperature and the
supernatant discarded. Excess lysis buffer was removed by washing the pellet twice with
cold PBS containing 2% FBS and then centrifuged at 2000 rpm for 5 minutes to obtain an
enzyme free cell pellet of single cells consisting of tumor and stromal cells. The cells
were counted using a hemocytometer and 1 million cells were stained with antibodies
against cell specific cell-surface antigens. To identify and quantitate each cell type, at
least two cell specific markers were used. A combination of antibodies was used to
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quantitate MDSCs (FITC-conjugated α-CD11b, Clone M/170 and PE-conjugated α-GR1, Clone RB68C5), mast cells (FITC-conjugated α-CD34, Clone RAM34 and APCconjugated α-CD117, Clone 2B8) and T-regs (FITC-conjugated α-CD4, Clone RM 4-5
and PE-conjugated α-FOXP3, Clone MF23). All antibodies were purchased from iCyt
Visionary Bioscience (Champaign, IL) and were used according to manufacturer
instructions at 0.25 µg per 106 cells in a 100 µl volume.
To each tube containing one million suspended cells, two cell surface antigen-specific
antibodies conjugated to two different fluorophores were added at 0.25 µg per 106 cells in
100 µl volume, and incubated in the dark at 4oC for one hour. After incubation, 1 ml of
PBS containing 2% FBS was added to the mixture and mixed well. Removal of excess
antibody from the mixture was done by centrifuged at 2000 rpm for 5 minutes and the
supernatant containing un-used antibody is discarded. This washing process was repeated
twice. Antibody labeled cells were then re-suspended in 500 µl of PBS containing 2%
FBS and analyzed for the various cell types using a Beckman Coulter FC-500 flow
cytometer. As controls, we analyzed cells from the spleen, bone marrow, and intestines of
non-tumor bearing, age-matched C57BL/6J and Balb/cByJ mice processed in a similar
manner.
Preparation of Sections for analysis by Confocal Microscopy: 14 to 15-week old ApcMin/+
mice were humanely sacrificed by cervical dislocation. Their intestines were isolated,
flushed with phosphate buffer saline (PBS) and cut open longitudinally as described
above. The tissues were fixed in 4% paraformaldehyde overnight. The fixed intestines
were then swiss-rolled and embedded in paraffin cassettes and left to dry overnight. 3-5
micron thick sections were cut from the swiss-rolled intestines and mounted on standard
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microscopy slides coated with poly-L-lysine.
CT26 tumor-bearing Balb/cByJ mice were sacrificed when the tumors reached 911 mm diameter. Their tumors were excised and washed with PBS to remove cell debris.
After overnight fixation in 4% paraformaldehyde, a small section was excised from the
tumor, embedded in paraffin. 3-5 micron thick sections were cut and mounted on
microscopy slides.
Immunofluorescence: The sections were deparaffinized, rehydrated then incubated in a
microwave oven at 950C with 0.01 M citrate buffer, pH 6.0 (Diagnostic Biosystem,
Pleasanton, CA) for 10 minutes for antigen retrieval. The sections were then blocked with
5% normal goat serum (Invitrogen, Frederick, MD) diluted with 1% IgG-free Bovine
serum albumin (BSA) in PBS for one hour. The sections were then incubated with
antibodies against monocytes (anti-CD11b), granulocytes (anti-Gr-1), mast cells (antiMCT1), or T-regs (anti-FOXP3). All antibodies were purchased from Abcam
(Cambridge, MA) and used at 1:200 dilutions (in 1% BSA in PBS). Anti-Mouse Cy-3
secondary antibody (Invitrogen, Frederick, MD) raised in goat was used to detect the
primary antibody targeted at each cell-type. The tissues were then stained with 4',6diamidino-2-phenylindole (DAPI, Invitrogen, Frederick, MD), a fluorescent stain that
binds strongly to A-T rich regions in DNA and is used to detect the nucleus. The slides
were imaged using a Zeiss LSM 510 confocal microscope. All images were captured
digitally at 40x magnification using filters for detecting emissions at 470 nm (DAPI) and
550 nm (Cy-3).

37

2.3 Results
2.3.1(a): Quantitation of MDSCs, mast cells, and T-regs in the spleen, bone marrow, and
tumor beds of ApcMin/+ mice and age-matched C57BL/6J mice by flow cytometry
In order to determine the effect of TS inhibitors on BMDCs in the tumor
microenvironment, it is important to establish the baseline quantities of these cells in
various organs and in tumor beds of the animal models that will be used in these studies.
Therefore, we carried out flow cytometry based quantitative analyses of MDSCs, mast
cells, and T-regs present in the tumor stroma, spleen, and bone marrow of 15-week old
ApcMin/+ mice and in age-matched wild type C57BL/6J mice. The results are shown in
Figure 2.1(A). We found that MDSCs, mast cells and T-regs constitute 4%, 1.1%, and
0.7%,respectively, of the cells isolated from the spleen, while in the bone marrow the
constitute 1.8% (MDSCs), 1.2% (mast cells), and 0.1% (T-regs) of the cell suspension,
respectively.
In contrast, when tissues from tumor bearing ApcMin/+mice were analyzed, much
higher percentages of the BMDCs were found in both spleen and bone marrow. As
shown Figure 2.1(B), the single cell suspensions contained 5% MDSCs, 4.8% Mast cells,
and 1.5% T-regs in the spleen. This represents approximately 1.3-, 4.4- and 2- fold
increases in MDSCs, mast cells and T-regs, respectively, as compared to that in the
spleens from wild type control C57BL/6J mice. The bone marrow consisted of 35%
MDSCs, 5% mast cells, and 0.6% T-regs. These indicated approximately 20-, 4.2- and 6fold increases in MDSCs, mast cells, and T-regs, respectively, as compared to the
percentages in wild type control bone marrow from C57BL/6J mice.
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Figure 2.1. Quantitation of MDSCs, Mast cells and T-regs in the
spleen, bone marrow and tumor of (A) C57BL/6J control mice and
(B) ApcMin/+ mice by flow cytometry. Spleen and bone marrow were
extracted from 15-week old C57BL/6J mice and ApcMin/+ mice and
tumors were excised from ApcMin/+ mice, stained with fluorochrome
conjugated antibodies for MDSCs (α-CD11b-FITC and α-Gr-1-PE),
Mast cells (α-CD34-FITC and α-CD117-APC) and T-regs (α-CD4-FITC
and α-FOXP3-PE). Cells were then analyzed and quantitated by flow
cytometry and plotted as percentage per million of the processed sample
mixture. This graph shows the basal level quantities of the cell types in
the bone marrow and spleen of the C57BL/6J control mice. Blue =
MDSCs, Red = mast cells, Green = T-regs
These data indicate that the presence of intestinal tumors induces the aggressive
generation of MDSCs in the bone marrow and subtle increase of the other cell types in
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the hematopoietic organs. The single cell suspensions from tumors contained
approximately 8% MDSCs, 6% mast cells and 3.8% T-regs. These data provided the
basis for assessing the effects of chemotherapy on these cells in later studies.

2.3.1 (b): Quantitate the target cell types in the spleen, bone marrow, and tumor in an
ectopic model by subcutaneous injection of CT26 cells into Balb/cByJ mice
To determine the extent of BMDC recruitment into tumor beds in a model with a more
advanced carcinoma, and to ensure that the recruitment was independent of the Min
allele, we analyzed the levels of BMDCs by quantitative flow cytometry of single cell
suspensions from tumors, spleen, and bone marrow obtained from 10-week old
Balb/cByJ mice bearing CT26 tumors. As controls, we compared these levels to that in
tissues from age-matched tumor-free Balb/cByJ mice. Figure 2.2(A) shows that in nontumor bearing Balb/cByJ mice, MDSCs, mast cells, and T-regs composed 1.3%, 0.7%
and 0.1%, respectively, of the cells in the spleen, while in the bone marrow, they
constituted 1.1%, 0.3%, and 0.2%, respectively, of the cell suspension.
Similar analyses conducted on age-matched Balb/cByJ mice bearing 9-11 mm
diameter tumors in the flank, showed a huge increase in the immune cell populations in
all the hematopoietic organs and in tumor beds, as shown in Figure 2.2(B). MDSCs, mast
cells, and T-regs constituted 8%, 5.9%, and 2.1% of cell suspensions from the spleen.
This indicated an increase in MDSCs, mast cells, and T-regs by approximately 6-, 8.5-,
and 21- fold, respectively, in the spleen of tumor bearing Balb/cByJ mice as compared to
that in the control tumor-free Balb/cByJ mice. MDSCs, mast cells and T-regs constituted
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approximately 16.4%, 7.7%, and 1%, respectively, of the bone marrow cells in CT26
tumor-bearing Balb/cByJ mice. This represents about a 15-, 26-, and 5- fold increase in
MDSCs, mast cells, and T-regs, respectively, in tumor bearing Balb/cByJ mice as
compared to the control tumor-free Balb/cByJ mice. MDSCs, mast cells, and T-regs
constituted approximately 13.2%, 3.6%, and 2.5% of the single cell suspension obtained
from tumors excised from these mice.
Taken together, the data indicate that the presence of tumors in mice correlated
with a large increase in the percentage of immune cells in various hematopoietic organs,
suggesting that the signals from the tumors may induce an increase or recruitment bone
marrow derived immune cells into both tumors and organs. The results indicate that
recruitment of BMDCs into the tumor beds is not a consequence of the loss of the APC
gene in the ApcMin/+ mice but is dependent on the presence of neoplastic cells. The data
from flow cytometric analyses further indicate that MDSCs, mast cells, and T-regs
infiltrate the tumors in large numbers. In addition, these cells are also found at elevated
levels in tissues such as the spleen and bone marrow in tumor bearing mice.
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Figure 2.2. Quantitation of MDSCs, Mast cells and T-regs in the
spleen, bone marrow and tumor of (A) Balb/cByJ control mice and
(B) CT26 tumor bearing Balb/cByJ mice by flow cytometry. Spleen,
bone marrow and tumors were extracted from 9-10 week old Balb/cByJ
mice and CT26 tumor bearing Balb/cByJ mice and tumors, and 1 million
cells were stained with fluorochrome conjugated antibodies to detect
MDSCs (α-CD11b-FITC and α-Gr-1-PE), mast cells (α-CD34-FITC and
α-CD117-APC), and T-regs (α-CD4-FITC and α-FOXP3-PE). Stained
cells were analyzed and quantitated by flow cytometry and plotted as
percentage per million of the processed sample mixture. This graph shows
the quantities of the different cell types in the bone marrow and spleen of
the Balb/cByJ control mice. Blue = MDSCs, Red = Mast cells, Green = Tregs
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These data show that hematopoietic derived cells are a major component of the
intestinal tumor microenvironment and support the notion that these cells can potentially
be harnessed as targets to enhance tumor specific efficacy of existing therapies. They
infiltrate into the tumor beds, and the presence of the tumors enhanced the level of
inflammatory cells in the hematopoietic organs.

2.3.2: Localization of MDSCs, mast cells and T-regs in the tumor stroma
To further assess the infiltration of the target cells in the tumor stroma, we used confocal
microscopy to localize the host-derived immune cells in the tumor bed. Tumor sections
were processed and stained with fluorescently labeled antibodies against cell-specific cell
surface markers. When imaged at 40x, we observed a massive infiltration by monocytes,
granulocytes, and mast cells and a limited presence of T-reg cells of the intestinal tumor
stroma in 15-week old ApcMin/+ mice and in the CT26 tumors implanted in 10-week old
Balb/cByJ mice. Figure 2.5 shows representative images of the intestinal tumor stroma
analyzed by a confocal microscopy. To represent the MDSCs, we analyzed the
infiltration of monocytes and granulocytes, two major sub-classes of MDSCs that are
frequently studied separately by immunofluorescence analysis. As shown in Figure 2.5A,
monocytes infiltrate the intestinal tumor stroma in high numbers and are distributed all
over the tumor bed. Granulocyte (Figure 2.5B) and mast cells (Figure 2.5C) also infiltrate
the intestinal tumors but are not as vastly distributed as monocytes. Tumor infiltrating Tregs on the other hand (Figure 2.4D), occupy very small regions of the tumor stroma and
make up a very low percentage of the tumor infiltrating immune cells. These results are
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consistent with the data obtained by flow cytometric shown in the previous section.
Tumors from the Balb/cByJ mice that were subcutaneously implanted with 1
million CT26 cells were processed and stained in a similar manner to localize monocytes,
granulocytes, mast cells, and T-regs in the tumor beds. Figure 2.6 shows representative
confocal images indicating the abundance of monocytes, granulocytes, and mast cells, as
well as the small number of T-regs localized to the tumor beds. Visual examination of
CT26 tumors indicate a more aggressive infiltration of monocytes and granulocytes as
compared to tumors in the ApcMin/+ mice (Figures 2.6 A and B vs Figures 2.5 A and B,
respectively). In comparison, mast cells, although abundant, are lower in number as
compared to monocytes and granulocytes (Figure 2.6C vs Figures 2.6A and B) in the
CT26-derived tumors. T-regs are the lowest abundant cells in both the adenomas in
ApcMin/+ mice and CT26-derived tumors in Balb/cByJ mice (Figure 2.5D and Figure
2.6D.
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Figure 2.3. Localization of Monocytes, Granulocytes, Mast cells and T-regs in
the intestinal tumor stroma of ApcMin/+ mice by confocal microscopy. Intestinal
sections were isolated from 15-week old ApcMin/+ mice, flushed with PBS, fixed
overnight in 4% paraformaldehyde, and embedded in paraffin cassettes. 3-5 micron
thick sections were cut from the paraffin embedded intestines and stained with
antibodies to detect monocytes (α-CD11b), granulocytes (α-Gr-1), mast cells (αMCT1) and T-regs (α-FOXP3) The antibody-labeled samples were incubated with an
anti-mouse secondary antibody conjugated to Cy-3, and then counter stained with
DAPI to stain the nucleus. The slides were analyzed and imaged using a Zeiss LSM
510 confocal microscope to confirm cell localization in the intestinal tumor stroma A)
Monocytes (CD11b - Red), B) Granulocytes (Gr-1 - Pink), C) Mast cells (MCT1 Yellow), D) T-regulatory cells (FOXP3 - White). Blue = DAPI (nucleus).
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Figure 2.4. Localization of Monocytes, Granulocytes, Mast cells and T-regs in
the CT26-derived tumors in Balb/cByJ mice, an ectopic model of colorectal
carcinoma. Tumors derived from CT26 cells were excised from the flanks of
Balb/cByJ mice, washed with saline solution, fixed overnight in 4%
paraformaldehyde and smaller sections from the tumors were embedded in paraffin
cassettes. 3-5 micron thick sections were cut from the embedded sections and stained
with antibodies to detect monocytes (α-CD11b), granulocytes (α-Gr-1), mast cells (αMCT1) and T-regs (α-FOXP3). The antibody-labeled samples were incubated with an
anti-mouse secondary antibody conjugated to Cy-3 and then counter stained with
DAPI to detect the nucleus. The cells were analyzed and imaged using a Zeiss LSM
510 confocal microscope imaged and their localization confirmed in the tumor stroma.
A) Monocytes (CD11b - Red), B) Granulocytes (Gr-1 - Pink), C) Mast Cells (MCT1 Yellow), D) T-regulatory cells (FOXP3 - White). Blue = DAPI (nucleus).
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Collectively, the results showed that MDSCs, mast cells and T-reg cells are
indeed abundant in the tumor beds at different stages of colorectal cancer, however, there
seems to be a higher level of recruitment of BMDCs by the more advanced and invasive
CT26-derived tumor in Balb/cByJ mice as compared to the early stage adenomas in
ApcMin/+ mice.

This is supported by data from both flow cytometric and confocal

microscopy analyses. It is possible that the stage of cancer progression might play an
important role in the ability of the cancer cells to recruit stromal cells into their
surrounding microenvironment. Thus the more advanced CT26 tumors can recruit
monocytes and granulocytes more aggressively than adenomas in ApcMin/+ mice.

2.4 Discussion
The tumor microenvironment consists of a variety of normal cells that behave differently
due to their close interaction with aberrant cancer cells. Tumor epithelium is known to
produce elevated levels of secreted molecules such as Chemokine (C-C motif) ligand 9
(CCL9) or Stromal Derived Factor 1 (SDF1) that actively recruit BMDCs to the tumor
stroma (Galon, Costes et al. 2006; McLean, Murray et al. 2011). These recruited cells
could function in different ways within the tumor stromal compartment, participating in
different stages and aspects of tumorigenesis. Pro-tumorigenic cells in the tumor microenvironment could promote tumor progression in the following ways: (a) Produce
cytokines that encourage survival and progression of tumor growth and recruitment of
other immune cells; (b) Enhance the production of cytokines such as IFN-γ, IL-6 or TNFα that promote a chronic inflammatory environment that supports tumor progression; (c)
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confer immune-suppressive properties that enable tumors to escape the host immunesurveillance mechanisms; and (d) interact with cancer cells directly by cell to cell contact
to provide them with pro-tumorigenic growth factors and cytokines.
Tumor-infiltrating stromal cells participate in one or more of these functions
simultaneously to nurture the cancer cells. They can be immune-suppressive like the
MDSCs and IL-17 secreting T-regs or they could be involved in tumor initiation or tumor
progression such as the mast cells. Some cells can promote metastasis such as
macrophage cells, or they could exist as undifferentiated monocytes that aid in tumor cell
circulation or epithelial to mesenchymal transition. Bone marrow derived stromal cells
are recruited by various molecular signals to the tumor microenvironment where they coevolve with the cancer cells at each stage of cancer progression by synergistic activation
of molecular pathways within both cells (Hanahan and Weinberg 2000; Hanahan and
Weinberg 2011)
Colorectal adenomas in human patients have been shown to initiate the aggressive
production of MDSCs in peripheral blood monocytes isolated from untreated, tumor
bearing patients. Circulating levels of MDSCs have been shown to increase by 5-10% in
patients diagnosed with stage III and IV advanced colorectal cancer (Kimura, McKolanis
et al. 2013; Zhang, Wang et al. 2013). In murine models using CT26 colon carcinoma
cell lines, CD11bhigh/GR-1intermediate MDSCs secrete TGF- upon stimulation with IL-13
resulting in reduced tumor immune-surveillance by cytotoxic T cells (Fichtner-Feigl,
Terabe et al. 2008). They have further been shown to be instrumental in promoting
peritoneal metastasis of colorectal cancer (Li, Wu et al. 2013). In another mouse model
using MC38 colon cancer cell lines that were subcutaneously implanted onto the flanks
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of C57BL/6J, there is a four-fold increase in the CD11b/Ly6G+ MDSC population in the
spleens as compared to that in the age-matched naïve wild type controls. The same study
showed that single cell preparations from tumors excised from these mice consisted of
50% MDSCs (Medina-Echeverz, Fioravanti et al. 2011). In an ectopic model using
MC38 in C57BL/6J mice, MDSCs induced high activity levels of pro-tumorigenic
pathways such as MAPK, NFkB, CXCL1, and CCL7 (Sinha, Okoro et al. 2008;
Ichikawa, Williams et al. 2011).
The number of mast cells has been reported to increase in human patients as colon
cancers progress from the adenoma to carcinoma stage. This quantitative value is neither
a prognostic factor, nor a predictive index for patient survival. Nevertheless, mast cells
are thought to participate in regulatory mechanisms that drive tumor progression

(Xia,

Ding et al. 2011). Gounaris and colleagues showed that mast cells in human colonic
adenomas and adenocarcinomas are critical for epithelial tumorigenesis and tissue
remodeling. Rodent mast cells associated with colorectal cancers have been studied more
extensively as compare to human patients. Murine mast cells reside either in mucosal or
connective tissues. Mucosal mast cells that populate the region around the epithelium of
the gastrointestinal tract are of particular interest because these tumor educated mast cells
play a variety of roles in the progression of colorectal cancer (Liu, Zhang et al. 2011).
They localize to the colonic lesions induced in Crj: CD-1 (ICR) mice treated with colonic
carcinogen azoxymethane, a model of inflammation associated colon carcinoma (Tanaka
and Ishikawa 2013). Mast cells have also been shown to promote tumor growth by
producing elevated levels of TNF- in the tumor stroma, and by assisting in stromal
remodeling and induction of angiogenesis (Colombo and Piconese 2009). Their
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importance in intestinal adenoma has been established through many studies, however the
roles that they play are highly contradictory and controversial (Sinnamon, Carter et al.
2008; Heijmans, Buller et al. 2012).
Early studies examining the role of T-regs in human colorectal cancer
demonstrated that CD4+CD25+ T-regs in peripheral blood played an important role in
heightened immune-suppression by inhibiting autologous HLA-A1 restricted CD4+
cytotoxic T lymphocytes (Mougiakakos, Choudhury et al. 2010). The ratio of memory
CD8+ T cells to FOXP3+ T-regs was found to be a predictive marker for patient survival
in colorectal cancer cohorts (Correale, Rotundo et al. 2010; Suzuki, Chikazawa et al.
2010). FOXP3+ cells abundantly infiltrate the mesenteric lymph nodes in mouse models
of intestinal cancer and have been shown to promote immune tolerance to intestinal
bacteria (Erdman and Poutahidis 2010).

In the ApcMin/+ mouse model of intestinal

adenomas, cancer promoting pro-inflammatory T-regs constitute 3-5% of intestinal
mononuclear preparations as analyzed by flow cytometry (Serebrennikova, Tsatsanis et
al. 2012).
Our results provide a baseline quantitative estimation and specific localization of
MDSCs, mast cells, and T-regs in the tumor stroma of adenomatous polyps of ApcMin/+
mice and in colon cancer carcinomas in the ectopic model using Balb/cByJ mice. We
highlighted the enhanced presence of MDSCs, mast cells, and T-regs in the
hematopoietic organs of the tumor bearing mice, and high levels of infiltration into the
tumor beds. These data suggest that the BMDCs respond to the presence of tumor cells in
rodents by accumulating in hematopoietic organs and by aggressively infiltrating the
tumor beds. It is possible that the immune cells respond to cancer cells as foreign agents
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and infiltrate the tumor in an attempt to „heal‟ the body of this foreign invasion. The
baseline measurement of MDSCs, mast and T-regulatory cells within the tumor stromal
location that we established in this section will provide the basis for further studies
examining the impact of therapeutic agents on these cells.
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CHAPTER 3
THE IMPACT AND KINETICS OF THYMIDYLATE SYNTHASE INHIBITORS ON
MDSC, MAST, AND T-REGULATORY CELLS
3.1 Introduction
While the impact of TS inhibitors on tumor cells has been widely studied, their effect on
the variety of BMDCs infiltrating the intestinal tumor is less well studied. The specific
cells types that may be direct targets of TS inhibitors have yet to be enumerated. In this
section, we focused our efforts in determining the effect of the TS inhibitor 5-FU on
MDSCs, mast cells, and T-regs, and the kinetics of their response to 5-FU. These cells
have been shown to interact with each other and to be critical for tumor initiation and
progression in ApcMin/+ mice (Clarke, Betts et al. 2006; Gounaris, Erdman et al. 2007;
Ling, Pratap et al. 2007; Colombo and Piconese 2009; Gounaris, Blatner et al. 2009;
Correale, Rotundo et al. 2010). 5-FU is thought to possess immunogenic properties that
could affect these cells in the tumor microenvironment. Understanding the impact of 5FU on these and other cells in the tumor microenvironment will allow us to understand
their role in tumor response to 5-FU and could provide the basis for developing therapies
that might enhance its anti-tumor efficacy.
Previous studies have shown that by genetically modifying the BMDCs
infiltrating the tumor stroma to make them resistant to TS inhibitors, rendered intestinal
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tumors to be also resistant to systemic treatment with a combination of the TS inhibitors
raltitrexed and 5-FU (Pena et al, unpublished data). The specific BMDCs in the tumor
stroma that may dictate tumor response to TS inhibition have not been studied.
Identification of these cells is necessary to determine if they can be specifically
genetically manipulated to enhance tumor response to TS inhibitors. Moreover,
understanding the mechanisms by which 5-FU directly affects these intestinal stromal
cells will facilitate our ability to harness them in order to enhance anti-tumor efficacy
while lowering drug induced toxicities to the surrounding normal cells.
MDSCs have previously been shown to be sensitive to 5-FU, as well as
gemcitabine treatment both in vitro, using immortalized MDSC cell lines derived from
Balb/c splenocytes, and in vivo using an EL4 thymoma mouse model.(Vincent, Mignot et
al. 2010). Anti-inflammatory T-regs in human colorectal cancer patients can respond to a
combination therapy consisting of 5-FU, oxaliplatin, and leucovorin (FOLFOX)
(Gonzalez-Aparicio, Alzuguren et al. 2011). This combination of drugs was shown to
reduce tumor burden and to deplete the number of anti-inflammatory T-regs in the
spleens of tumor bearing animals (Ghiringhelli, Larmonier et al. 2004). Not much is
known about the response of mast cells to 5-FU administration. To date, there have been
no studies carried out examining the effect of TS inhibitors on MDSCs, mast cells, and Tregs simultaneously, in the tumor stroma of colorectal cancer. In this chapter, we
quantitatively assessed the effect of a single dose of 5-FU on MDSCs, mast cells, and Tregs in the intestinal tumor stroma in ApcMin+ mice and in the ectopic model of CT26
mouse colon carcinoma cells subcutaneously implanted onto Balb/cByJ mice. The results
showed that MDSCs, and to a lesser extent, T-regs, were selectively sensitive to 5-FU but
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mast cells were not responsive. Similar results were obtained in both ApcMin/+ mice,
which had early stage adenomas, and in the ectopic model representing advanced stage
carcinoma, suggesting that their response to the therapy was independent of the stage of
carcinogenesis. We also examined their response in hematopoietic organs such as spleen
and bone marrow in both normal and tumor bearing mice. To assess their role in tumor
response to therapy, we determined the effect of 5-FU on MDSCs, mast cells and T-regs
in chimeric mice wherein the BMDCs in the stromal compartment were made resistant to
TS inhibitors, while tumor cells were sensitive to the therapy. The results showed that in
these mice, the MDSCs and T-regs were no longer sensitive to 5-FU, but were in fact
resistant to the drug. The data indicate that BMDCs in the tumor microenvironment can
be direct targets of 5-FU and that these cells can be genetically manipulated to alter
tumor response to therapy.

3.2 Material and Methods
Cells: GP+E86 producer cells were obtained from ATCC (Manassas, VA). The cells
were stably transfected with the retroviral vector pMSCV-OptecTS (MOTS) containing
the gene for E. coli TS that was optimized for expression in mammalian cells (Shaw,
Berger et al. 2001) to generate the producer cell line GP+E86 (MOTS). The cells were
cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% heat
inactivated Fetal Bovine Serum (FBS) (Atlanta Biologicals, Lawrenceville, GA), 2
mmol/L L-glutamine, and 1× penicillin/streptomycin (Mediatech, Manassas, VA) at 37oC
and 5% CO2 in a humidified atmosphere.
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Mice: Balb/cByJ and ApcMin/+ mice were purchased from Jackson Laboratories (Bar
Harbor, ME, USA) but were bred and maintained at the Mouse Experimentation Core
Facility of the Center for Colon Cancer Research at the University of South Carolina
(USC), Columbia, SC. All aspects of the animal experiments have been conducted in
accordance with the guidelines and approval of the USC Institutional Animal Care and
Use Committee.
Drug administration: A stock solution of 5 mg/ml of 5-FU (Sigma-Aldrich, St. Louis,
MO) was dissolved in PBS and filter sterilized using 0.2 micron syringe filters. Two
groups of ApcMin/+ mice (twenty mice per group) were injected intraperitoneally (i.p,)
with either 5-FU (50 mg/kg) or PBS as a control. In the Balb/cByJ ectopic model, tumor
size was monitored after subcutaneous injection. 5-FU or PBS was administered when
the tumor diameter reached 9-11 mm. The drug dose of 50 mg/kg is similar to that used
in previous studies and shown to have the maximum depleting effect on MDSCs in vivo,
in the EL4 thymoma model (Vincent, Mignot et al. 2010).
Tissue harvest and analysis: Five ApcMin/+ mice from each group were humanely
sacrificed at 3, 5, 7 and 10 days after drug administration. For the ectopic model, two
tumor bearing mice each from the PBS or 5-FU-treated groups were analyzed also at 3, 5,
7, and 10 days post 5-FU administration. Bone marrow, spleen and tumors were isolated
from these animals and processed for analyses by flow cytometry, as described before.
Figure 3.1 is a schematic diagram of the schedule of drug administration in the 15-week
old ApcMin/+ mice and subsequent harvest and analyses of the tissues at different time
points post 5-FU administration.
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50 mg/kg 5-FU

Days 0

3

5

7

10

Harvest cells from tumors and
quantitate target cell-types using flow
cytometry
Figure 3.1. Schedule of drug administration and time points for cell analyses. 5FU was administered i.p. in the respective tumor bearing mice. The day of drug
injection is designated as Day 0. On days 3, 5, 7, 10 days post 5-FU administration,
spleen, bone marrow, and tumors were harvested from the animals, single cell
suspensions were prepared, and the target cells quantitated by flow cytometry.

Bone marrow transplantation:
Isolation of bone marrow: Four-week old C57BL/6J donor mice were injected with one
dose of 150 mg/kg 5-FU administered i.p. to ablate the committed cells from the bone
marrow and induce the progenitor cells to initiate the cell cycle. The donor mice were
sacrificed after 48 hours and their bone marrow was flushed from the femur and tibia
with sterile PBS containing 2% FBS using a 21-gauge needle. The bone marrow was
washed twice with 1 ml of sterile PBS to remove traces of FBS and pre-stimulated by
culturing for two days in DMEM supplemented with 15% FBS, 20 ng/ml recombinant
interleukin 3 (rIL-3, (Thermo Scientific, Rockford, IL), 50 ng/ml recombinant interleukin
6 (rIL-6, Thermo Scientific, Rockford, IL) and 50 ng/ml recombinant rat stem cell factor
(rSCF) (Peprotech, Rockhill, NJ) at 37o C and 5% CO2 in a humidified atmosphere.
Transduction by Co-culture: Sub-confluent GP+E86 (MOTS) producer cells were
prepared prior to the start of co-culture by treating each plate with 10 ug/ml mitomycin C
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(Calbiochem, San Diego, CA) for 90 minutes to stop their division and growth. The cells
were washed 4 times in PBS and re-plated in 100-mm tissue culture dishes. The prestimulated bone marrow cells prepared above, were harvested by tapping gently on the
side of each plate, and by drawing up 5-10 ml cell suspension. The plate is then washed
with PBS twice to harvest as many cells as possible. Care was taken to prevent cell lysis.
10 ml of the media containing bone marrow cells was added to each plate of producer
cells and polybrene (hexadimethrine bromide, purchased from Sigma-Aldrich, St. Louis,
MO) was added to the co-culture media to a final concentration of 6 ug/ml. The bone
marrow and producer cells were co-cultured for 48 hours and then harvested for
transplantation or plating in methylcellulose semi-solid media.
Harvest and transplant: Age-matched recipient ApcMin/+ mice were lethally irradiated
with 900 Gy administered at 200 Gy/minute using a Varian Clinac Linear Accelerator.
The transduced bone marrow cells were harvested by carefully removing the media from
the co-culture plates. The media was centrifuged in an Eppendorf 5430R centrifuge for 5
minutes at 2000 rpm at room temperature. The cell pellet was washed twice with PBS to
remove traces of FBS. 1 to 3 million bone marrow progenitor cells were injected into the
recipient ApcMin/+ mouse by tail vein injection.
Tissue processing: Tumors, spleen, and bone marrow tissues were processed for analyses
by flow cytometry as described in the previous chapter.
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3.3 Results
3.3.1 (a) Effect of 5-FU on target cell types in ApcMin/+ mice
We analyzed the effect of single dosage of 5-FU on the various cell types and compared
them to the tumor stromal cells in control age-matched tumor bearing mice injected with
PBS. We administered a single dose of 5-FU or PBS to ApcMin/+ mice and determined the
effect on the percentages of MDSCs, mast cells, and T-regs in the tumor beds, spleen,
and bone marrow at 3, 5, 7, and 10 days post injection. The results in Figure 3.2 shows
the fold change in the percentages of the target cell-types post 5-FU administration, as
compared to those in mice treated with PBS. All animals were sacrificed and the tissues
processed on the same day. As shown in Figure 3.2 the MDSCs in the tumor beds are the
most sensitive cells to systemic treatment with 5-FU. They are depleted by almost 50% in
the tumor beds of ApcMin/+ mice, with maximum depletion on days 3 to 5 after 5-FU
administration. The same sensitivity was observed in the spleen (Figure 3.2) and bone
marrow, with the bone marrow exhibiting the highest level of depletion on day 5.
Gradually though, MDSC levels recovered from the drug treatment and were restored to
normal pre-treatment levels in the tumor beds, spleen, and bone marrow by day 10 after
5-FU administration. In contrast, the number of mast cells in the tumor beds increased by
almost two-fold at 5 days after drug administration (Figure 3.2). This was accompanied
by a corresponding two-fold decrease in the spleen at five days (Figure 3.3). This inverse
relationship suggested that mast cells might be mobilized from the spleen to the bone
marrow in response to 5-FU treatment. On the hand, the number of mast cells in bone
marrow, which is physiologically not a typical localization for mast cells, remains
relatively unchanged throughout the course of this study (Figure 3.3). T-regs in the tumor
58

beds appear to be sensitive to 5-FU and are depleted within three days after treatment,
however, they quickly recover to pre-treatment levels within five days (Figure 3.2).
There is no significant effect on T-regs in the spleen (Figure 3.3), and in bone marrow
(Figure 3.3). It is important to note though that assessing the impact on T-regs is
complicated by the fact that there are very low levels of T-regs in all three tissues
examined. For example, the percentage of T-regs change from 2.1% in the tumors of PBS
treated ApcMin/+ mice to 1.4% three days post 5-FU treatment. Also as observed in the
tumor bed, T-regs recover quickly by the 5th day, showing a very transient response to 5FU. They do not show a pronounced response to 5-FU in the hematopoietic organs, and
seem to display a delayed response to the drug decreasing from the original level by 0.22
folds transiently at around day 7 (Figure 3.3).

*
*
*

Figure 3.2. Effect of 5-FU on MDSCs, Mast cells, T-regs in tumor beds of
ApcMin/+ mice. 15-week old ApcMin/+ mice were administered with PBS or 50 mg/kg 5FU. At 3, 5, 7, and 10 days post drug injection, tumors from 5 mice in each group
were excised. Single cell suspensions were prepared and then 1 million cells were
stained with antibodies to detect MDSCs (α-CD11b and α-Gr-1), mast cells (α-CD34
and α-CD117), and T-regs (α-CD4 and α-FOXP3). Stained cells were quantitated by
flow cytometric analyses.
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*

*
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Figure 3.3. Effect of 5-FU on MDSCs, Mast cells, T-regs in the
spleens of ApcMin/+ mice. 15-week old ApcMin/+ mice were administered
with PBS or 50 mg/kg 5-FU. At 3, 5, 7, and 10 days post drug injection,
spleens from 5 mice in each group were isolated. Single cell suspensions
were prepared and then 1 million cells were stained with antibodies to
detect MDSCs (α-CD11b and α-Gr-1), mast cells (α-CD34 and α-CD117),
and T-regs (α-CD4 and α-FOXP3). Stained cells were quantitated by flow
cytometric analyses.

*
*
*

Figure 3.4. Effect of 5-FU on MDSCs, Mast cells, T-regs in the bone
marrow of ApcMin/+ mice. 15-week old ApcMin/+ mice were administered
with PBS or 50 mg/kg 5-FU. At 3, 5, 7, and 10 days post drug injection,
bone marrow was flushed from the femur and tibia of 5 mice in each
group. Single cell suspensions were prepared and then 1 million cells
were stained with antibodies to detect MDSCs (α-CD11b and α-Gr-1),
mast cells (α-CD34 and α-CD117), and T-regs (α-CD4 and α-FOXP3).
Stained cells were quantitated by flow cytometric analyses.
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3.3.1(b) Effect of 5-FU on MDSCs, Mast cells and T-regs in an ectopic mouse model
Our earlier findings suggested that MDSCs, mast cells and T-regs infiltrate the tumor
stroma of both adenoma and carcinoma stages of colorectal cancer. In the previous
section we determined the effect of 5-FU on these cells in early stage adenomas. In this
section, we determined the effect of 5-FU on these cells in a subcutaneous model of colon
carcinoma cells, a more advanced stage of the disease.

We injected CT26 colon

carcinoma cells into the flank of Balb/cByJ mice, allowed the tumors to develop to a
diameter of 9-11 mm, and then subjected the mice to 50 mg/kg 5-FU or PBS, harvested
tissues, and processed and analyzed as described previously..
The results shown in Figures 3.5, 3.6, and 3.7 indicate that in a model of advanced
stage carcinoma, the MDSCs are also selectively sensitive to 5-FU, while mast cells are
resistant, and T-regs are moderately affected by the drug. These results further indicate
that the kinetics of the effect of 5-FU on MDSCs, mast and T-reg cells are independent of
the stage of cancer progression. MDSCs in the Balb/cByJ-CT26 carcinoma model appear
to recover quicker from the effects of 5-FU as compared to those in the adenomas in
ApcMin/+ mice. Instead of the gradual recovery from 5-FU by day 10 post injection seen in
ApcMin/+ mice, MDSCs in tumor beds of the Balb/cByJ-CT26 ectopic model recover to
pre-treatment levels by day 7, with 50% reduction in their numbers only at day 5. This
response could be attributed to the higher recruiting ability of the CT26 carcinoma cells
allowing MDSCs to be more quickly mobilized to the CT26 tumor stroma to replace the
diminished levels after 5-FU administration. Taken together, though, these results show
that MDSCs in the stroma of tumors at different stages of colorectal cancer progression,
and in hematopoietic organs such as spleen and bone marrow, are similarly depleted in
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response to 5-FU therapy, with maximum effects seen on day 5. Similar to ApcMin/+ mice,
mast cells in the Balb/cByJ-CT26-carcinoma model are resistant to 5-FU in the tumor
beds and exhibit a two-fold increase in their numbers after 5-FU administration. The
depletion of mast cells in the spleen in response to 5-FU is not as pronounced as in the
ApcMin/+ mouse, with the number of splenic mast cells reduced only very slightly by
approximately 0.1 fold.
Quantitatively, mast cells were not adversely affected in the spleens or bone
marrow of the ectopic colorectal tumor-bearing Balb/cByJ animals. In the bone marrow,
we observed an immediate but transient two-fold increase in mast cells on day 5, but the
number of mast cells returned to pre-treatment level on day 7. The impact of 5-FU on Tregs was more gradual in the carcinoma model as compared to the adenoma model. Their
levels were diminished to less than 50% five days after 5-FU administration, after which
they slowly recovered to pre-treatment level by day 10. Understanding the involvement
of inflammatory cells at all stages of tumor development will allow us to develop
customized therapy schedules that might enhance the antitumor efficacy of TS inhibitors.
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*

Figure 3.5. Effect of 5-FU on MDSCs, Mast cells, and T-regs in tumor beds of
Balb/cByJ mice implanted with CT26 cells. Mice with tumors that were 9-11 mm
in diameter were administered with PBS or 50 mg/kg 5-FU. At 3, 5, 7, and 10 days
post drug injection; tumors from mice in each group were excised and debulked into
single cell suspensions and then stained with antibodies to detect MDSCs (α-CD11b
and α-Gr-1), mast cells (α-CD34 and α-CD117), and T-regs (α-CD4 and α-FOXP3).
The stained cells were quantitated by flow cytometry.

*
*

Figure 3.6. Effect of 5-FU on MDSCs, mast cells, and T-regs in spleens of tumor
bearing Balb/cByJ mice. Mice bearing tumors with a 9-11 mm diameter were
administered with PBS or 50 mg/kg 5-FU. At 3, 5, 7, and 10 days post drug injection;
spleens from mice in each group were isolated. Single cell suspensions of splenocytes
were stained with antibodies to detect MDSCs (α-CD11b and α-Gr-1), mast cells (αCD34 and α-CD117), and T-regs (α-CD4 and α-FOXP3). The stained cells were
quantitated by flow cytometry.
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Figure 3.7. Effect of 5-FU on MDSCs, mast cells, and T-regs in the bone marrow
of tumor bearing Balb/cByJ mice. Mice bearing tumors with a diameter of 9-11 mm
were administered with PBS or 50 mg/kg 5-FU. At 3, 5, 7, and 10 days post drug
injection, bone marrow from mice in each group were isolated. Single cell suspension
of bone marrow was stained with antibodies to detect MDSCs (α-CD11b and α-Gr-1),
mast cells (α-CD34 and α-CD117), T-regs (α-CD4 and α-FOXP3). The stained cells
were quantitated by flow cytometry.

3.3.2 Determine the kinetics of response to 5-FU in mice transplanted with ecTS
overexpressing chemo-resistant marrow
After quantifying the effect of 5-FU on MDSCs, mast and T-reg cells from tumor bearing
ApcMin/+ and Balb/cByJ mice, we studied the kinetics of the target cells‟ response to 5-FU
administration in ApcMin/+ mice transplanted with TS over-expressing bone marrow. In
earlier studies, we found that in chimeric ApcMin/+ mice wherein BMDCs in the tumor
microenvironment were made resistant to TS inhibitors by transplanting marrow that was
overexpressing ecTS while the tumor cells were chemosensitive to the therapy, tumors
were also rendered resistant to TS inhibitors. In the current experiment, the goal was to
determine the role of the target BMDCs in mediating tumor resistance to 5-FU in the
chimeric mice. 4- weeks old ApcMin/+ mice were lethally irradiated and transplanted with
bone marrow overexpressing E.coli TS to create chimeric mice whose bone marrow
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derived tumor stroma responds differently to chemotherapy as compared to the cancer
cells. A schematic diagram of the procedure for creating the chimeric mice is shown in
the in Figure 1.6. After complete engraftment of the transplanted marrow, the mice were
treated with 50 mg/kg 5-FU followed by analyses of the target cell populations as
described in previous sections.

As controls, ApcMin/+ mice transplanted with non-

transduced, chemo-sensitive marrow and non-transplanted ApcMin/+ mice were also
analyzed.
The results showed that MDSCs in the tumor beds of mice transplanted with drug
resistant bone marrow expressing the E .coli. TS increased by approximately 1.8 fold
after 5-FU administration in contrast to the MDSCs in mice transplanted with chemosensitive non-transduced marrow and in non-transplanted mice wherein the MDSCs in
the tumor beds were depleted (Figure 3.8). Ten days post 5-FU administration, the
MDSC population in the tumor beds of chimeric mice remained at least 1.5 fold higher
than those in the control mice, indicating that they retained their resistance to TS
inhibitors throughout the course of the treatment. Interestingly, MDSCs in the spleen and
bone marrow in the transplanted mice, retained their sensitivity to 5-FU and were
depleted by approximately 50% in both organs, as shown in Figures 3.9 and 3.10. It is
however noteworthy that the bone marrow in the mice transplanted with chemoresistant
bone marrow recovered quicker as compared to the chemo-sensitive controls, supporting
the notion that transplanting mice with chemoresistant bone marrow might provide them
with some level of myeloprotection against 5-FU induced toxicity.
The results in Figure 3.8 show that mast cells in the tumor beds of the chimeric
mice remained resistant to 5-FU, showing an increase of 1.5 to 2-fold in drug treated
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mice as compared to the that was similar to that in mice transplanted with chemoresistant
marrow or non-transplanted mice. However, in contrast to the results seen in the untransplanted mice or transplanted mice with chemosensitive stroma, mast cells in the
spleens of mice transplanted with chemoresistant marrow were 1.8-fold higher on day 5
post 5-FU administration (Figure 3.9) rather than being depleted. Mast cells in the bone
marrow show a certain threshold level of resistance to 5-FU throughout the course of
study. Till day 7 of the treatment all three groups of 5-FU treated mice show an upsurge
of mast cell numbers ranging from 1.5 fold in chemo-sensitive mice to 2.5 fold in the
mice transplanted with drug resistant bone marrow expressing the E .coli. TS. By day 10
after 5-FU administration though, the quantity of mast cells gets lowered to nearly the
same numbers as the PBS control groups. This trend is seen in all the three groups of
mice, namely, untransplanted, chemo-sensitive, and resistant marrow carrying ApcMin/+
mice.
The results in Figure 3.8 further indicate that, T-regulatory cells in the chimeric
mice were resistant to 5-FU in tumor beds, with a 1.7 fold higher levels on day 3, as
compared to the tumor beds in un-transplanted mice or mice transplanted with chemosensitive bone marrow. Similar to the MDSCs, T-regs in the tumor beds of chimeric mice
were also resistant to 5-FU throughout the course of the study. They showed little or no
effect in response to 5-FU in the spleen, suggesting that the chemo-resistant bone marrow
might skew the BMDC response to 5-FU in the hematopoietic organs. Since bone
marrow is not the normal residence of differentiated cells such as mast cells and T-regs, it
was not an ideal organ for determining the effect of TS inhibitors in these cells. In
addition, mast cells and T-regs in the bone marrow behave differently from those in the
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tumor beds, since these cells play different roles in the normal stroma of non-cancerous
organs.

ApcMin/+ (Tumor beds)

Figure 3.8. Comparison of the effect of 5-FU on MDSCs, Mast cells, and T-regs
in the tumor beds of ApcMin/+ mice that were non-transplanted or transplanted
with non-transduced chemosensitive or ecTS-transduced chemoresistant bone
marrow. 15-weeks old ApcMin/+ mice from the different groups were administered
with 50 mg/kg 5-FU. At 3, 5, 7, and 10 days post drug injection; tumors from 5 mice
in each group were excised. Single cell suspensions were prepared from the tumors
and stained with antibodies to detect MDSCs (α-CD11b and α-Gr-1), mast cells (αCD34 and α-CD117), T-regs (α-CD4 and α-FOXP3) and the stained cells were
quantitated by flow cytometry.
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ApcMin/+ mice (Spleen)

Figure 3.9. Comparison of the effect of 5-FU on MDSCs, Mast cells, and T-regs
in the spleens of ApcMin/+ mice that were non-transplanted or transplanted with
non-transduced chemosensitive or ecTS-transduced chemoresistant bone
marrow. 15-weeks old ApcMin/+ mice from the different groups were administered
with 50 mg/kg 5-FU. At 3, 5, 7, and 10 days post drug injection, spleens from 5 mice
in each group were isolated. Single cell suspensions were prepared from the spleens
and stained with antibodies to detect MDSCs (α-CD11b and α-Gr-1), mast cells (αCD34 and α-CD117), T-regs (α-CD4 and α-FOXP3) and the stained cells were
quantitated by flow cytometry.
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ApcMin/+ mice (Bone Marrow)

Figure 3.10. Comparison of the effect of 5-FU on MDSCs, Mast cells, and T-regs
in the bone marrow of ApcMin/+ mice that were non-transplanted or transplanted
with non-transduced chemosensitive or ecTS-transduced chemoresistant bone
marrow. 15-weeks old ApcMin/+ mice from the different groups were administered
with 50 mg/kg 5-FU. At 3, 5, 7, and 10 days post drug injection, bone marrow from
the femur and tibia of 5 mice in each group was isolated. Single cell suspension was
prepared from the bone marrow and stained with antibodies to detect MDSCs (αCD11b and α-Gr-1), mast cells (α-CD34 and α-CD117), T-regs (α-CD4 and αFOXP3) and the stained cells were quantitated by flow cytometry.

3.4 Discussion
The recognition of the direct impact of 5-fluorouracil on the tumor stromal compartment
of colorectal cancer in vivo is crucial to identifying BMDCs that could influence or
determine tumor response to therapy using TS inhibitors. A number of studies have been
done to elucidate the effect of 5-FU on the tumor stromal cells in a variety of cancers. For
example, 5-FU was found to activate the cleavage of caspase-3 and BH3 interactingdomain death agonist expression in CD8+ T cells in vitro (Cheng, Liu et al. 2004) and has
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been shown to deplete neutrophils in the peripheral blood of primates (Gillio, Gasparetto
et al. 1990). Its effect on MDSCs, mast cells, and T-regs, bone marrow derived cells in
the tumor stroma that have been shown to play a role in the development of colorectal
cancer, has not been studied simultaneously . Our study simultaneously examined the
impact of 5-FU on these cells and the kinetics of their response in the tumor bed and in
the hematopoietic organs like bone marrow and spleen. It was important to study the
effect of 5-FU on the cells in the environment of the hematopoietic organs and in the
tumor beds in order to assess if the effect of drug was systemic or targeted only in the
tumor stroma due to changes in the genetic signature and behavior of the BMDCs in the
tumor beds in response to signals initiating from the tumor cells. Moreover, examining
the impact of a single dose of 5-FU over time allowed us to evaluate the response of the
target cell-types after the system recovers from the impact of drug and potentially assess
the role they play in tumor recurrence post therapy.
The results from our studies show for the first time, that MDSCs but not mast
cells are sensitive to 5-FU in the intestinal tumors. This response was the same
irrespective of the location of MDSCs, tumor, spleen or bone marrow, in tumor bearing
mice. T-regs on the other hand are present in very low numbers in the tumor beds, that
the effect of 5-FU on them was not very pronounced. It had previously been shown that
MDSCs undergo caspase-3 and -7 mediated apoptosis within 5 days after treatment with
5-FU in vitro (Vincent, Mignot et al. 2010). However, it was not known whether this
effect was sustained even after the removal of the therapy in vivo or if this response was
only transient. The data we obtained from un-transplanted ApcMin/+ mice and the
Balb/cByJ mice that were subcutaneously implanted with CT26 cells showed that the
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depletion of MDSCs in the tumor beds was a transient effect which peaked at 5 days
post-treatment. Upon removal of 5-FU, MDSCs gradually re-populate the tumor stroma
and return to pre-treatment levels. Similar effects were observed in the hematopoietic
organs. On the other hand, mast cells were unaffected by 5-FU treatment and appear to be
recruited to the tumor beds from the spleen.
When transplanted with BMDCs that have been genetically modulated to
overexpress E.coli. TS gene, that had previously been shown to confer resistance to TS
inhibitors, the MDSCs in tumor stroma were rendered resistant to 5-FU at all time-points
examines post drug administration. This data shows that, tumor infiltrating MDSCs can
be manipulated ex vivo such that they exhibit resistance to TS inhibition. More
importantly, this showed that 1) MDSCs might play a role in mediating tumor response to
5-FU, and 2) manipulating the sensitivity of the cells in the tumor microenvironment can
alter tumor response to the therapy. This raises the possibility that increasing the
chemosensitivity of these cells might also increase the sensitivity of tumors to the therapy
and in this case enhance the anti-tumor efficacy of 5-FU therapy. We further found that
MDSCs in the hematopoietic organs were not as resistant to 5-FU as compared to the
MDSCs in tumor beds. It is known that colorectal tumors have a much higher level of TS
as compared to the normal regions. A plausible explanation could be that the difference
in the sensitivity of the MDSCs is due to the fact that MDSCs in tumor stroma may have
co-evolved with the cancer cells and their presence in a chronically inflamed environment
in tumor associated stroma confers enhanced resistance as compared to MDSCs in nontumor stroma.
5-FU has been shown to inhibit mastopoiesis in vitro at a concentration of 1 ug/ml
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administered continuously for 14 days and in vivo when administered at 150 mg/kg at 2
days after drug injection (Ophir, Berenshtein et al. 1993). This inhibition of mastopoiesis
was transient and followed by a gradual recovery of the cells after 5-FU treatment. This
data suggested that mast cells can be targeted by 5-FU. Our data indicates that this effect
does not happen at the lower dose that was used in our experiments. However, although
the higher concentration of the drug was effective, its potential anti-tumor effects are
abrogated by its toxic effect by depleting the committed progenitor cells in vivo. Such a
dose will be sub-lethal causing extensive hematopoietic damage as a side effect. It is also
possible that, upon 5-FU treatment, mast cells might be recruited from the hematopoietic
organs or might be differentiating from their progenitor stage and migrating to the tumor
bed to help protect the tumors or to recover from drug induced toxicity (Okayama and
Kawakami 2006). Additional experiments need to be performed to verify this possibility.
It is also possible that in vivo, a much higher concentration of 5-FU is needed to target
mast cells as compared to MDSCs. In our studies, we only used one dose of 5-FU, 50
mg/kg to minimize its toxic side-effects. It might be worthwhile to perform these studies
at higher concentrations of 5-FU to test this possibility. The ultimate goal of these
studies, however, are to develop strategies to enhance the toxicity of 5-FU to tumor cells
without having to increase the dosage in order to minimize drug induced toxicities. We
are therefore pursuing strategies using combinations of 5-FU with drugs that inhibit mast
cell activity to determine of this is a viable combination that might enhance the antitumor efficacy of 5-FU (Tisdale and Pena, unpublished data.). In summary, the data
suggests that the target cell types examined, – MDSCs, mast and T-regs cells may all
contribute in different ways to the refractile response to 5-FU in animals transplanted
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with genetically engineered HSCs expressing a drug resistant ecTS gene (Pena et.al.,
unpublished data). These data will be useful in designing strategies that either target
BMDCs or genetically modify MDSCs to enhance tumor response to therapeutic agents.
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CHAPTER 4
MECHANISMS UNDERLYING THE IMPACT OF 5-FLUOROURACIL ON MDSCS,
MAST CELLS, AND T-REGULATORY CELLS
4.1 Introduction
Inhibition of apoptosis and the aberrant proliferation of colonic epithelium, which is
typical in the tumor microenvironment, aid the serration or unmanageable growth of the
crypt epithelium and facilitate the transition from hyperplastic to dysplastic environment.
The tumor stromal cells residing within the micro-environment co-evolve with the cancer
cells and over time, they behave in response to molecular signals from the cancer cells to
promote tumor progression. Because of this, we propose that an effective anti-neoplastic
drug should be able to induce apoptosis not only in aggressively proliferating cancer cells
but in the associated tumor stromal cells as well. In order to determine if a BMDC in the
tumor stroma has the potential to enhance the efficacy of TS inhibitors, it is essential to
know its response, i.e., undergo apoptosis, to 5-FU is administration.
The results in the previous section showed that 5 days after 5-FU administration,
there is a rapid depletion of MDSCs while mast cells were resistant to the effects of 5FU. In this section, we examined the mechanisms underlying the differential response of
the three cell types to 5-FU. First, we determined if the cells undergo apoptosis, in
response to treatment with 5-FU.

Since TS inhibitors are targeted against actively
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proliferating cells, we then measured the proliferative indices of the cells to determine if
this was the underlying reason for the vulnerability of MDSCs to 5-FU.
Irreparable DNA strand breaks usually results in apoptosis mediated by a cascade
of cleaved caspases. In animal models of colorectal cancer, apoptosis of tumor cells in
response to anti-neoplastic drugs is largely mediated by caspase-3 and caspase-7
dependent pathways. Previous studies have shown that 5-FU can induce the cleavage of
caspase 3 and caspase 7 (Stevenson, Allen et al. 2011; Kim, Kim et al. 2013). Poly
(ADP-ribose) polymerase 1 (PARP-1) is a target of caspase cleavage which leads its
inactivation, a hallmark of late apoptosis. In the case of colorectal cancers, cleavage of
caspase 3 and 7 is the main mediator of PARP1 cleavage at aspartic acid 214 and glycine
215 which generates two PARP-1 fragments of 24 kDA and 89 kDA each. This renders
PARP-1 inactive and engages the cell on a path towards programmed cell death.
The apoptotic effect of 5-FU is usually amplified in aggressively proliferating
cells. One marker for active proliferation is the nuclear protein Ki-67. During interphase,
the Ki-67 antigen is detected in the nucleus, but during mitosis, most of the protein is
transported to the chromosomal surface. The Ki-67 protein is functional during all active
phases of the cell cycle, but is absent from the resting cells (in G0 phase). Thus, Ki-67 is a
nuclear protein that is strictly associated with active cellular proliferation and is not
expressed during G0 phase, making it a useful marker to identify actively proliferating
cells. Antibodies to Ki-67 have been successfully used in a variety of cancers to identify
aggressively proliferating cells. This marker has also been used as a labeling index to
identify the clinical course or staging of the disease. All aggressively proliferating cells
inevitably express Ki-67 protein in their nuclear and chromosomal surfaces.
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MDSCs are immature, undifferentiated cells that are broadly classified into
monocytes and granulocytes. We examined the apoptotic status of both cell-types that
compose the MDSC population. We then performed similar analyses on mast cells which
were resistant to 5-FU. The results indicated that MDSCs but not mast cells undergo
apoptosis in response to 5-FU. Analyses of their proliferative indices indicated that
MDSCs are more highly proliferative as compared to the mast cells, thereby underscoring
their enhanced vulnerability to 5-FU. Elucidating the impact and vulnerability of the
various BMDCs that make up the tumor microenvironment will allow us to understand
their role in tumor response to therapy and their role in promoting tumor cell death or
recurrence post therapy. We could then exploit these interactions to tilt the balance
toward tumor killing and regression by simultaneously targeting tumor cells and stromal
cells in the tumor microenvironment.

4.2 Materials and Methods
Mice: Balb/cByJ mice, C57BL/6J-ApcMin/J mice (ApcMin/+) and C57BL/6J mice were
purchased from Jackson Laboratories (Bar Harbor, ME, USA) but were bred and
maintained at the Mouse Core Facility of the Center for Colon Cancer Research at the
University of South Carolina (USC), Columbia, SC. All aspects of the animal
experiments have been conducted in accordance with the guidelines and approval of the
USC Institutional Animal Care and Use Committee.
Drug Administration and harvest: Three ApcMin/+ mice aged 15-weeks were administered
with PBS and three ApcMin/+ mice with 50 mg/kg 5-FU. Animals were humanely
sacrificed 5 days after PBS or 5-FU administration. Their intestines were isolated,
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divided into four sections, flushed with PBS to remove fecal material, and cut open
longitudinally. The tissues were fixed overnight in 4% paraformaldehyde. The fixed
intestines were “swiss-rolled”, embedded in paraffin cassettes, and left to dry overnight.
3-5 micron thick sections were cut from the swiss-rolled intestines and mounted on polyL-lysine coated microscopy slides.
Immunofluorescence: The sections were deparaffinized, rehydrated, and then incubated
in a microwave oven at 95oC with 0.01 M citrate buffer, pH 6.0 (Diagnostic Biosystem,
Pleasanton, CA) for 10 minutes for antigen retrieval. Sections were blocked with 5% goat
serum (Invitrogen, Frederick, MD) and 5% Normal Donkey serum (Jackson Laboratory,
Bar Harbor, ME) diluted in 1% BSA in PBS for one hour. To identify apoptotic cells, the
samples were incubated overnight with a mixture of primary antibodies against cleaved
PARP-1 (Rabbit polyclonal, 1:200 dilution, Santa Cruz Biotechnology, Santa Cruz, CA
USA) and a cell-type specific cell surface marker such as CD11b for monocytes, Gr-1 for
granulocytes, or MCT1 for mast cells (all the antibodies are rat monoclonal used at 1:200
dilution, all from Abcam, Cambridge, MA) in 1% BSA in PBS.

To assess the

proliferative indices of the various cell types, the samples were incubated overnight with
a mixture of primary antibodies against Ki-67 (Rabbit polyclonal, 1:800 dilution, Abcam,
Cambridge, MA) and a cell-type specific surface marker, such as CD11b for monocytes,
Gr-1 for granulocytes, or MCT1 for mast cells (all antibodies are rat monoclonal
antibodies used at 1:200 dilutions) in 1% BSA in PBS. The next day, the samples were
washed with 1% BSA in PBS and then incubated with a mixture of goat anti rat
secondary antibody conjugated to Cy-3 (1:200 dilution, Invitrogen, Frederick, MD) and
donkey anti-rabbit secondary antibody conjugated to Cy-5 (1:100 dilution, Jackson
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Laboratory, Bar Harbor, ME) for 1 hour at 37oC. The sections were again washed with
1% BSA/PBS for 30 minutes at room temperature and then stained with DAPI for
nucleus. Stained sections were cover-slipped using ProLong Gold anti-fade reagent
(Invitrogen, Frederick, MD).
Imaging and Quantitation: The slides containing sections stained with the various
combinations of primary antibodies, i.e., against CD11b and cPARP-1, Gr-1 and cPARP1, MCT1 and cPARP-1, CD11b and Ki-67, Gr-1 and Ki-67, and MCT1 and Ki-67 were
imaged using Zeiss LSM Meta 510 confocal microscope. For each antibody combination,
3 sections obtained from 3 different mice were stained and a minimum of approximately
100 field view images were captured at 40 X magnification from the different slides. For
each field view image, we manually counted the number of cells that stained positively
for the specific cell type examined and then counted the number of cells that also stained
positively for cleaved PARP to determine the number of apoptotic cells, or for Ki-67 to
determine the number of proliferating cells. Apoptotic or proliferative indices were
calculated as the percentage of cells that stained for both the cell surface marker and
cleaved PARP or Ki-67 against the total number of cells that stained positively for the
specific cell surface marker.
Statistical Analysis: Statistical analysis was performed on the two separate groups of
mice either treated with PBS or 5-FU, to compare the proportion or percentage of cells
expressing both cell-specific surface marker, as well as either apoptosis marker cleaved
PARP-1 or proliferation marker Ki-67. The mice used in the study were randomly
selected from a population of mice, the tumors observed were a sample from a population
of tumors within one mouse and the field view observed is a sample from a population of
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field views within one tumor. The tumors were nested within the mice and were not
identical to each other. Also, the numbers of tumors in each mouse were varied. The field
views were nested within the tumors of the mice and the number of regions of field views
per tumor was not identical. The PBS vs 5-FU treatment groups were constant throughout
the study, while random effects were considered to be those associated with mice, tumors
and field views, with the additional restriction that there was nesting aspect to these
random effects.
Statistical analysis for this section was done using glmer function in the lme4
package of the widely used statistical software R. PBS and 5-FU treated mice were
considered as the two separate groups analyzed by a generalized linear model with a
binomial distribution and logit link function. The result was represented by the box and
whisker histogram with the median values flanked by upper and lower 25% quartile with
whiskers showing the maximum and minimum data points.

4.3 Results
4.3.1 Apoptotic response of the target cell-types to 5-fluorouracil
We used double immunofluorescence staining of intestinal tumor sections, to determine if
the 5-FU mediated depletion of MDSCs is due to apoptosis. Typically, MDSCs are
identified by a combination of antibodies against CD11-b and Gr-1, however, we were
unable to successfully stain with both antibodies in combination with a marker for
apoptosis. Thus, in order to gauge the effect of 5-FU on these cells, we separately stained
with a combination of antibodies against CD11b and cPARP-1 or with a combination of
antibodies against Gr-1 and cPARP-1.

The apoptotic index was expressed as the
79

percentage of cells that stained for both markers against the total number of cells that
stained positively for the cell specific surface marker. The representative slide in Figure
4.1 shows a drastic increase in the apoptotic index of monocytes at 5 days after 5-FU
administration, as compared to the PBS-treated mice. From a total of 198 field views, we
calculated that in PBS-treated mice, 20.25% of the CD11b-positive cells also stained
positively for cPARP-1, indicating a baseline level of apoptosis in these cells (Table 4.1).
In contrast, upon treatment with 5-FU, 62.2% of the CD11b-positive cells also stained
positive for cPARP-1, a 42% increase over the basal level. Statistical analysis of the data
collected from the absolute numbers shown in Figure 4.2 indicated a significant increase
in the number of apoptotic cells upon treatment with 5-FU.

PBS

5-FU

Figure 4.1. Apoptosis induced in monocytes at 5 days after 5-FU administration.
Intestinal tissues from ApcMin/+ mice were fixed in 4% paraformaldehyde overnight
and embedded into paraffin cassettes. 3-5 micron sections were cut and double stained
with rat monoclonal primary antibody against CD11b (a marker for monocytes) and
rabbit polyclonal primary antibody against c-PARP-1 (a marker for apoptosis). The
samples were then incubated with Cy-3-conjugated goat anti-rat secondary antibody
and Cy5-conjugated donkey anti-rabbit secondary antibody, respectively. 198 total
images were taken from the PBS and 5-FU samples together. Representative field
views of confocal images of intestinal sections from PBS or 5-FU treated mice are
shown. Red = CD11b positive cells (monocytes), Green = cleaved PARP-1 (apoptotic
cells). Double positive cells indicate apoptotic monocytes.
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Table 4.1. Apoptosis induced in monocytes 5 days after 5-FU administration.

Total numbers of monocytes (CD11b-positive red cells) and the total number of
apoptotic monocytes (CD11b-positive, red and c-PARP-positive, green cells) were
counted from n=100 field views each for PBS and 5-FU treated mice (n=3 mice per
treatment group). The percentage of apoptotic CD11b+ cells in each group was
calculated by dividing total apoptotic monocyte cells by total number of monocytes in
all the field views. The table shows the total numbers of cells and the percentages of
apoptotic monocytes in PBS vs 5-FU treated ApcMin/+ mice.

Figure 4.2. Box plots of the number of apoptotic monocytes in PBS versus 5-FU
treated mice at 5 days post treatment. This figure is a graphical presentation of the
statistical analyses of the number of cells undergoing apoptosis in response to 5-FU.
P-Hat is the estimated proportion for the particular combination of Treatment, Mouse,
Tumor, and field view, and is obtained by dividing the number of apoptotic monocyte
cells by the total number of monocyte cells examined.
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We performed a similar analysis of granulocytic cells. The results in Figure 4.3
shows representative field views of double immunofluorescent staining for granulocytes
and the apoptosis marker, cleaved PARP-1. As expected, the granulocytes behaved
similarly to monocytes, demonstrating a dramatic increase in the apoptotic index in
response to 5-FU administration as compared to PBS-treated cells. The granulocytes
showed a baseline apoptotic level of 16% in PBS treated ApcMin/+ mouse intestinal tumor
stroma which increased to 67% in 5-FU-treated mice, representing an approximately 4fold increase as shown in Table 4.2. This statistically significant difference in apoptotic
indices is further shown in Figure 4.4 by a box plot of number of apoptotic cells counted
from the 200 field views of the images taken from the treatment groups.

PBS

5-FU

Figure 4.3.
Apoptosis induced in granulocytes at 5 days after 5-FU
administration. Intestinal tissues from ApcMin/+ mice were fixed in 4%
paraformaldehyde overnight and embedded into paraffin cassettes. 3-5 micron
sections were cut and double stained with rat monoclonal primary antibody against
Gr-1 (a marker for granulocytes) and rabbit polyclonal primary antibody against cPARP-1 (a marker for apoptosis). The samples were then incubated with Cy-3conjugated goat anti-rat secondary antibody and Cy5-conjugated donkey anti-rabbit
secondary antibody, respectively. 200 total images were taken from the PBS and 5-FU
samples together. Representative field views of confocal images of intestinal sections
from PBS or 5-FU treated mice are shown. Red = Gr-1 positive cells (granulocytes),
Green = cleaved PARP-1 (apoptotic cells). Double positive cells indicate apoptotic
granulocytes.
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Table 4.2. Apoptosis induced in granulocytes 5 days after 5-FU administration.

Total numbers of granulocytes (Gr-1-positive red cells) and the total number of
apoptotic granulocytes (Gr-1-positive, red and c-PARP-positive, green cells) were
counted from n=100 field views each for PBS and 5-FU treated mice (n=3 mice per
treatment group). The percentage of apoptotic Gr-1+ cells in each group was
calculated by dividing total apoptotic granulocyte cells by total number of
granulocytes in all the field views. The table shows the total numbers of cells and the
percentages of apoptotic granulocytes in PBS vs 5-FU treated ApcMin/+ mice.

Figure 4.4. Box plots of the number of apoptotic granulocytes in PBS versus 5FU treated mice at 5 days post treatment. This figure is a graphical presentation of
the statistical analyses of the number of granulocyte cells undergoing apoptosis in
response to 5-FU. P-Hat is the estimated proportion for the particular combination of
Treatment, Mouse, Tumor, and field view, and is obtained by dividing the number of
apoptotic granulocyte cells by the total number of granulocyte cells examined.
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In contrast to the results obtained with MDSCs, similar analyses of mast cells in
the intestinal tumor sections, showed an insignificant increase in apoptotic response to 5FU administration from a baseline value of 17% in PBS-treated mice to 19% in 5-FU
treated mice. Representative immunofluorescence confocal images in Figure 4.5 showed
very low numbers of MCT1 positive mast cells with positive staining for cleaved PARP.
The total number cells that were positive for MCT1 and/or cleaved PARP-1 staining field
views are shown in Table 4.3. The numbers indicate only a 2% increase in the apoptotic
index between the PBS and 5-FU treated mice. Finally, Figure 4.6 shows the box plots of
a total of 93 field views from both the groups together, indicating no significant
difference in the apoptotic indices between PBS and 5-FU treated mice.

Figure 4.5. Apoptosis induced in mast cells at 5 days after 5-FU administration.
Intestinal tissues from ApcMin/+ mice were fixed in 4% paraformaldehyde overnight
and embedded into paraffin cassettes. 3-5 micron sections were cut and double stained
with rat monoclonal primary antibody against MCT1 (a marker for mast cells) and
rabbit polyclonal primary antibody against c-PARP-1 (a marker for apoptosis). The
samples were then incubated with Cy-3-conjugated goat anti-rat secondary antibody
and Cy5-conjugated donkey anti-rabbit secondary antibody, respectively. 93 total
images were taken from the PBS and 5-FU samples together. Representative field
views of confocal images of intestinal sections from PBS or 5-FU treated mice are
shown. Red = MCT1 positive cells (mast cells), Green = cleaved PARP-1 (apoptotic
cells). Double positive cells indicate apoptotic mast cells.
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Table 4.3. Apoptosis induced in mast cells 5 days after 5-FU administration.

Total numbers of mast cells (MCT1-positive red cells) and the total number of
apoptotic mast cells (MCT1-positive, red and c-PARP-positive, green cells) were
counted from n=100 field views each for PBS and 5-FU treated mice (n=3 mice per
treatment group). The percentage of apoptotic MCT1+ cells in each group was
calculated by dividing total apoptotic mast cells by total number of mast cells in all
the field views. The table shows the total numbers of cells and the percentages of
apoptotic mast cells in PBS vs 5-FU treated ApcMin/+ mice.

Figure 4.6. Box plots of the number of apoptotic mast cells in PBS versus 5-FU
treated mice at 5 days post treatment. This figure is a graphical presentation of the
statistical analyses of the number of mast cells undergoing apoptosis in response to 5FU. P-Hat is the estimated proportion for the particular combination of Treatment,
Mouse, Tumor, and field view, and is obtained by dividing the number of apoptotic
mast cells by the total number of mast cells examined.
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These results from these analyses corroborate with the data obtained by flow
cytometric analyses obtained in earlier sections, demonstrating that mast cells were not
depleted in response to 5-FU administration. All the samples analyzed by fluorescence
immunohistochemical staining showed a baseline level of 15-20% apoptotic cells in the
intestinal tumor stroma of control PBS treated mice. This number probably represents
normal turnover or homeostasis in the intestinal tumor stroma. The samples used in the
analyses for apoptotic indices were obtained from 3 different mice in each group for each
of the different cell-types. The results of the trends presented here are consistent within
each mice in each treatment group.

4.3.2 Proliferative indices of the target cell-types in PBS and 5-FU treated mice
TS inhibitors specifically target actively proliferating cells, thus, we examined the
proliferative index of the MDSCs and mast cells to determine if this is the underlying
reason for their differential response to 5-FU. As in the previous experiment, we used an
immunofluorescence based analyses to determine the percentages of proliferating cell
types in PBS or 5-FU treated mice. Fixed sections on slides were stained with antibodies
against cell-specific surface markers and with an antibody against Ki-67 as a marker for
proliferation. The number of cells that stained positive for the cell surface markers and
those that stained for both cell surface marker and Ki-67 were determined, and the
percentage of double stained cells against the total number of cell surface marker positive
cells was used as a measure of the proliferative indices. The results showed that in PBS
treated mice, the monocytes and granulocytes had much higher percentages of
proliferating cells as compared to mast cells. Figures 4.7 and 4.9 show representative
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images of intestinal tumor sections stained for monocytes and granulocytes, respectively.
The data in Tables 4.4 and 4.5 indicate that the baseline proliferation indices in PBStreated mice were 26.23% and 32.01% for monocytes and granulocytes, respectively. In
response to 5-FU, the proliferation rates decreased by approximately two-fold to 11.89%,
and 17.13% for monocytes, granulocytes, respectively. Box plots of the statistically
significant changes in the percentage of proliferating cells in response to 5-FU are shown
in Figures 4.8 and 4.9.

Figure 4.7. Proliferation levels of monocytes at 5 days after 5-FU administration.
Intestinal tissues from ApcMin/+ mice were fixed in 4% paraformaldehyde overnight
and embedded into paraffin cassettes. 3-5 micron sections were cut and double stained
with rat monoclonal primary antibody against CD11b (a marker for monocytes) and
rabbit polyclonal primary antibody against Ki-67 (a marker for proliferation). The
samples were then incubated with Cy-3-conjugated goat anti-rat secondary antibody
and Cy5-conjugated donkey anti-rabbit secondary antibody, respectively. 216 total
images were taken from the PBS and 5-FU samples together. Representative field
views of confocal images of intestinal sections from PBS or 5-FU treated mice are
shown. Red = CD11b positive cells (monocytes), Green = Ki-67 (proliferating cells).
Double positive cells indicate proliferating monocytes.
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Table 4.4. Reduction in the level of proliferation of monocytes 5 days after 5-FU
administration.

Total numbers of monocytes (CD11b-positive red cells) and the total number of
proliferating monocytes (CD11b-positive, red and Ki-67-positive, green cells) were
counted from n=100 field views each for PBS and 5-FU treated mice (n=3 mice per
treatment group). The percentage of proliferating CD11b+ cells in each group was
calculated by dividing total proliferating monocyte cells by total number of monocytes
in all the field views. The table shows the total numbers of cells and the percentages
of proliferating monocytes in PBS vs 5-FU treated ApcMin/+ mice.

Figure 4.8. Box plots of the number of proliferating monocytes in PBS versus 5FU treated mice at 5 days post treatment. This figure is a graphical presentation of
the statistical analyses of the number of monocyte cells undergoing proliferation in
response to 5-FU. P-Hat is the estimated proportion for the particular combination of
Treatment, Mouse, Tumor, and field view, and is obtained by dividing the number of
proliferating monocyte cells by the total number of monocyte cells examined.
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Figure 4.9.
Proliferation levels of granulocytes at 5 days after 5-FU
administration. Intestinal tissues from ApcMin/+ mice were fixed in 4%
paraformaldehyde overnight and embedded into paraffin cassettes. 3-5 micron
sections were cut and double stained with rat monoclonal primary antibody against
Gr-1 (a marker for granulocytes) and rabbit polyclonal primary antibody against Ki-67
(a marker for proliferation). The samples were then incubated with Cy-3-conjugated
goat anti-rat secondary antibody and Cy5-conjugated donkey anti-rabbit secondary
antibody, respectively. 194 total images were taken from the PBS and 5-FU samples
together. Representative field views of confocal images of intestinal sections from
PBS or 5-FU treated mice are shown. Red = Gr-1 positive cells (granulocytes), Green
= Ki-67 (proliferating cells). Double positive cells indicate proliferating granulocytes.

Table 4.5. Reduction in the level of proliferation of granulocytes 5 days after 5FU administration.

Total numbers of granulocytes (Gr-1-positive red cells) and the total number of
proliferating granulocytes (Gr-1-positive, red and Ki-67-positive, green cells) were
counted from n=100 field views each for PBS and 5-FU treated mice (n=3 mice per
treatment group). The percentage of proliferating Gr-1+ cells in each group was
calculated by dividing total proliferating granulocyte cells by total number of
granulocytes in all the field views. The table shows the total numbers of cells and the
percentages of proliferating granulocytes in PBS vs 5-FU treated ApcMin/+ mice.
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Figure 4.10. Box plots of the number of proliferating granulocytes in PBS versus
5-FU treated mice at 5 days post treatment. This figure is a graphical presentation
of the statistical analyses of the number of granulocyte cells undergoing proliferation
in response to 5-FU. P-Hat is the estimated proportion for the particular combination
of Treatment, Mouse, Tumor, and field view, and is obtained by dividing the number
of proliferating granulocyte cells by the total number of granulocyte cells examined.

Similar analyses for mast cells showed a much lower basal level of proliferation
of 7.06%, approximately 3-5 folds lower as compared to monocytes and granulocytes.
Representative slides of immunofluorescent double staining with antibodies against
MCT1 and the Ki-67 proliferation marker in Figure 4.11 shows very little or no colocalization of the two antibodies. This is further supported by the data in Table 4.6
obtained from 50 field each views of the PBS and 5-FU treated samples showing only 7%
of mast cells proliferating in PBS treated mice that is reduced to 3% in 5-FU treated
mice. Although, we observed a 50% reduction from 7% to 3% in the 5-FU treated mice,
the absolute numbers of proliferating mast cells are very low as compared to proliferating
monocytes or granulocytes. These numbers are consistent with the data obtained from
analyses done by flow cytometric methods. Taken together, the data indicate that MDSCs
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have a much higher proliferation rate that is approximately 3-5 fold higher than that in
mast cells that potentially render them more sensitive to the effects of 5-FU.

PBS

5-FU

Figure 4.11. Proliferation levels of mast cells at 5 days after 5-FU administration.
Intestinal tissues from ApcMin/+ mice were fixed in 4% paraformaldehyde overnight
and embedded into paraffin cassettes. 3-5 micron sections were cut and double stained
with rat monoclonal primary antibody against MCT1 (a marker for mast cells) and
rabbit polyclonal primary antibody against Ki-67 (a marker for proliferation). The
samples were then incubated with Cy-3-conjugated goat anti-rat secondary antibody
and Cy5-conjugated donkey anti-rabbit secondary antibody, respectively. 100 total
images were taken from the PBS and 5-FU samples together. Representative field
views of confocal images of intestinal sections from PBS or 5-FU treated mice are
shown. Red = MCT1 positive cells (mast cells), Green = Ki-67 (proliferating cells).
Double positive cells indicate proliferating mast cells.
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Table 4.6. Reduction in the level of proliferation of mast cells 5 days after 5-FU
administration.

Total numbers of mast cells (MCT1-positive red cells) and the total number of
proliferating mast cells (Gr-1-positive, red and Ki-67-positive, green cells) were
counted from n=100 field views each for PBS and 5-FU treated mice (n=3 mice per
treatment group). The percentage of proliferating MCT1+ cells in each group was
calculated by dividing total proliferating mast cells by total number of mast cells in all
the field views. The table shows the total numbers of cells and the percentages of
proliferating mast cells in PBS vs 5-FU treated ApcMin/+ mice.

Figure 4.12. Box plots of the number of proliferating mast cells in PBS versus 5FU treated mice at 5 days post treatment. This figure is a graphical presentation of
the statistical analyses of the number of mast cells undergoing proliferation in
response to 5-FU. P-Hat is the estimated proportion for the particular combination of
Treatment, Mouse, Tumor, and field view, and is obtained by dividing the number of
proliferating mast cells by the total number of mast cells examined.
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4.4 Discussion
MDSCs are a major contributor for tumor immune escape due to their strong immunesuppressive abilities. MDSCs are present at such high levels in tumor bearing murine
models because aggravation of inflammation effectively enhances MDSC generation as
well as immune-suppressive ability. Under inflamed conditions induced by tumors,
MDSCs show a much higher resistance to apoptosis as compared to the normal healthy
conditions. Nevertheless, in tumor bearing rodent models, MDSCs have been reported to
be depleted from the animal model system by the use of specific drugs like 5-FU and
gemcitabine (Vincent, Mignot et al. 2010). This depletion has been attributed to the
activation of a cleaved caspase 3 and 7 mediated apoptotic pathway, post drug treatment
(Vincent, Mignot et al. 2010) in immortalized MDSC cell lines but it has not been
elucidated in vivo and has especially not been studied in colorectal cancer model. It has
also been reported that MDSCs are susceptible to regulation by the Fas mediated
pathway. Mast cells on the other hand, have though been implicated in the initiation of
polyps, progression of colorectal tumors and mobilization of MDSCs, their response to 5FU has not been studied before. Thus, with the goal of identifying the underlying
mechanism behind 5-FU mediated MDSC depletion and to uncover the rationale behind
mast cells insensitivity to the therapy, we examined the proliferative and apoptotic status
of these cells pre- and post- 5-FU administration. We have studied both the sub-classes of
MDSCS separately, namely, monocytes and granulocytes along with mast cells in the
intestinal tissues from the same group of tumor bearing animals. Our experiments
simultaneously examined the Fas-Caspase mediated apoptosis, manifesting itself as the
cleavage of PARP-1 along with active-cell-cycle Ki-67 expression in the same murine
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model system of ApcMin/+ mice.
From our results, it can be postulated that monocytes and granulocytes show a
similar range of apoptotic indices 5 days post 5-FU administration. This could be the
underlying reason for the measurable depletion of MDSCs from the quantitative analyses
done in the previous section. These high apoptotic indices were not observed with the
mast cells, which substantiates our earlier results. Monocytes and granulocytes also seem
to have a relatively higher level of proliferation in untreated animals as compared to the
mast cells. Although, 5-FU quantitatively reduced the absolute number of proliferating
mast cells, the depletion was not as prominent as MDSCs. Also, there is a possibility that
5-FU might be targeting some of the mast cells in the tumor beds and this depletion is
being compensated by maturation or recruitment of other mast cell progenitors, hence not
showing any measurable effect of the drug during flow cytometry assays. Nevertheless,
our study indicated that 5-FU does not target the existing mast cells in the tumor beds as
immensely as monocytes and granulocytes. The data from Ki-67 experiments point
towards the possibility that the mast cells are not as sensitive as MDSCs because of their
much lower rate of proliferation. This is an interesting result because it identifies MDSCs
as the potential target cells, which could be utilized to develop strategies to enhance
tumor sensitivity by combining 5-FU with other anti-inflammatory or anti-neoplastic
drugs (i.e., IL-β inhibitors (Bruchard, Mignot et al. 2013)). We could extend this research
by sensitizing mast cells to 5-FU therapy by targeting pathways that are crucial in
maintaining their active polyp-inducing state. It is also possible that since mast cells are a
differentiated cell-type, their turn-over rate in the tumor stroma can be targeted such that
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there is a reduction in tumor associated mast cells that, in turn, could limit or prevent the
mobilization of MDSCs and T-regs to the stroma.
Proliferation and apoptosis appear to go hand in hand in deciphering the impact of
5-FU on BMDCs in the tumor microenvironment. Both aspects can correlate to the effect
of 5-FU on the target cell-types. As a TS inhibitor, 5-FU non-selectively targets
proliferating cells including both cancer and non-cancer proliferating cells. This is
substantiated by the data showing enhanced PARP cleavage in monocytes and
granulocytes and not in mast cells.

95

CHAPTER 5
CONCLUSION AND FUTURE DIRECTIONS

5.1 Conclusion
The results from this study emphasize on the role of host derived immune cells
originating from the bone marrow and infiltrating the tumor microenvironment on tumor
response to therapy, specifically to 5-FU, a TS inhibitor. These tumor stromal cells could
be sensitive to TS inhibitor therapy and prone to 5-FU attack, such as MDSCs, or could
be insensitive to TS inhibition, such as the Mast cells. Each of the cell-types uniquely
contributes to tumor survival, progression, and metastasis. This project examined three
target cells which have the potential to dictate tumor response to therapy and influence
the manner in which the tumor recovers from anti-neoplastic therapy. This project
postulates that certain cells are more intriguing than others, with respect to their response
to therapy, owing to their proliferation rate that could potentially make them vulnerable
to 5-FU dosing. 5-FU is known to cause apoptosis in cancer cells as well as in rapidly
proliferating normal cells in the patient. It is critical to reduce drug induced toxicity while
enhancing the efficacy and specificity of the drug so that it can target only cancer and
tumor associated stromal cells. The results from this study indicate stromal cells derived
from the bone marrow can be exploited to develop methods to sensitize the tumor to TS
inhibitor therapy. The proof-of-the-principle studies that we have conducted, wherein
bone marrow cells in the tumor microenvironment that were made resistant to TS
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inhibitors also rendered tumor cells resistant to these inhibitors, suggest that these cells
can be exploited to enhance tumor response to 5-FU. Cells such as monocytes and
granulocytes, can be further modulated to enhance tumor sensitivity to the therapy. They
can also be genetically modified to modulate tumor response so that the rebound of
cancer cells from the therapy and therefore, time to tumor recurrence is extended.

1. Localized and Quantitated MDSCs, Mast Cells,
T-regulatory Cells in the Tumor Microenvironment
2. MDCSs and to a lesser extent, T-regs are direct targets of
5-FU, while Mast cells are not
3. MDSCs but not Mast cells may be vulnerable to 5-FU
because they are actively proliferating and they undergo
apoptosis in response to 5-FU
Figure 5.1. Schematic of conclusion: This presents a schematic of all the
experiments behind the various aims and sections of this project.

5.2 Future Directions
The results from these studies point to a number of experiments that can be pursued in the
future. First, TS inhibitors can be combined with other drugs that target cells that may
are resistant to the therapy, such as mast cells. Mast cells are thought to promote tumor
recurrence to therapy, and by inhibiting them tumor relapse after 5-FU treatment might
be prolonged or inhibited. Mast cell inhibitors such as Cromolyn, Nedocromil, or TNF
may be used in combination with 5-FU to study their effect on tumor burden and tumor
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recurrence. Studies from other labs have shown that loss of MDSCs in response to 5-FU
can activate the recruitment of CD8+ killer T cells that further enhance the killing of
tumor cells by 5-FU (Bruchard, Mignot et al. 2013). However, the dying MDSCs can
also activate the NLRP3 inflammasome which results in the release of IL1-B that
promotes the recruitment of CD4+ helper T cells that aids in tumor recurrence post
therapy. This raises the possibility of using inhibitors against IL-1 in combination with
5-FU attenuate the strong inflammatory response and block the recruitment of protumorigenic CD4+ T cells..
Finally, it is also critical to study the impact of 5-FU on other cells in the tumor
microenvironment such as neutrophils, tumor associated macrophages, mesenchymal
stem cells, myofibroblasts, and cancer-associated fibroblasts among many other celltypes, to determine their role in dictating tumor response to chemotherapy. Such studies
have not been undertaken before. Furthermore, one of the major goals of this project is to
be able to specifically target tumor and tumor stromal with the therapy, while sparing the
normal cells from drug induced toxicity and side-effects. The use of promoters that are
specifically expressed in the tumor stroma to drive the expression of chemosensitizing
genes in stromal cells will be useful in achieving this goal.
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